Gene expression profiling is increasingly important in human health research and applications (1 ). Unfortunately, the human tissue samples required for this process, particularly those from healthy individuals, are not safely and easily available. Therefore, the use of peripheral blood mononuclear cells (PBMCs) as surrogate material for high-throughput analysis of gene expression is currently being explored. These cells are involved in a large variety of immune-related diseases, including infection and cancer. Moreover, in recent studies, characteristic sets of transcriptional changes in PBMCs were associated with physiologic or pathologic states (2-4 ). Thus, a PBMC transcriptome may be used as an individual's health sensor, a concept referred to as the sentinel principle (5 ).
Gene expression profiling is increasingly important in human health research and applications (1 ) . Unfortunately, the human tissue samples required for this process, particularly those from healthy individuals, are not safely and easily available. Therefore, the use of peripheral blood mononuclear cells (PBMCs) as surrogate material for high-throughput analysis of gene expression is currently being explored. These cells are involved in a large variety of immune-related diseases, including infection and cancer. Moreover, in recent studies, characteristic sets of transcriptional changes in PBMCs were associated with physiologic or pathologic states (2) (3) (4) . Thus, a PBMC transcriptome may be used as an individual's health sensor, a concept referred to as the sentinel principle (5 ) .
In large multicenter studies, the reliable and reproducible detection of transcript concentrations from PBMCs requires standardization of blood sampling and an efficient method of conservation. Indeed, many preanalytical factors during collection, processing, and storage of blood specimens may affect RNA and its subsequent use as a biomarker (6 ) . Although numerous technical and clinical aspects of blood sampling have been addressed (7) (8) (9) , comprehensive data on the long-term storage and stability of RNA from PBMCs are needed. Here we report experiments performed over 15 months to test the preanalytical conditions involved in blood collection procedures and PBMC storage. Blood samples were collected from healthy donors into EDTA and sodium heparin tubes. RNA extractions were performed on isolated PBMCs stored at Ϫ80°C up to 15 months in 4 different lysis buffers. Using spectrometry and real-time PCR, we compared the concentration, purity, integrity, and stability of the total RNA. We propose a quality-assured and controlled protocol of PBMC banking for further mRNA expression analysis.
After informed consent was obtained from 12 unrelated adult volunteers, whole blood (10 mL) was collected by standardized venipuncture in EDTA (EDTA-blood; n ϭ 12) and heparin (heparin-blood; n ϭ 12) tubes (Vacutainer TM ; Becton Dickinson) and processed for PBMC preparation. Briefly, blood samples were homogenized with 10 mL of Hanks Balanced Salt Solution, Modified (SigmaAldrich). PBMCs were prepared by Ficoll density-gradient centrifugation (Ficoll-Paque TM PLUS; Amersham) at 300g for 30 min at 20°C. The ring of high-density PBMCs was isolated and washed twice in 50 mL of Hanks buffer. After cell survival was determined with the trypan-blue exclusion test, the PBMC concentration was normalized to 10 6 cells/mL in Hanks buffer. PBMC populations were evaluated by microscopic observation after May-Grunwald-Giemsa staining. After centrifugation for 6 min at 700g (4°C), 200 L of cell lysis buffer was immediately added to the PBMC pellet. Four different commercially available buffers were tested (n ϭ 24 for each buffer, including 12 . The PBMC lysates were used to extract total RNA immediately (t 0 ) or after storage at Ϫ80°C for 3, 5, 10, and 15 months (t 3 , t 5 , t 10 , and t 15 , respectively).
For total RNA extraction, we used an automated process with the MagNA Pure LC instrument (Roche Diagnostics) and the MagNa Pure LC RNA Isolation Kit I according to the manufacturer's instructions, including DNase treatment. Purified RNA was eluted at 70°C with 100 L of low-salt buffer. Total RNA quality and quantity were assessed in 2 ways. In the first method, we estimated the RNA concentration by ultraviolet absorbance at 260 nm (1 absorbance unit at 260 nm ϭ 40 ng/L RNA) and the RNA purity by measuring the ratio of absorbance at 260 nm and 280 nm (1.8 Ͻ A 260 /A 280 Ͻ 2.1 for pure RNA). Total RNA was run on 1% agarose gels to check size and integrity. In the second method, RNA from each sample was assessed for integrity by a 2-step reverse transcription-PCR assay for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; NM_002046). cDNA synthesis was performed at 37°C for 60 min with 80 ng of extracted RNA, 0.25 g of oligo(dT) 15 primer, and 200 U of Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega). After each reverse transcription, cDNA was amplified by a standard real-time protocol in the LightCycler instrument (Roche Diagnostics). The 20-L PCR reaction for the GAPDH gene included 1ϫ LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics), 4 mM MgCl 2 , 0.2 M each of 5Ј-ACGGATTTGGTCGTAT-TGGG-3Ј (forward primer) and 5Ј-CGCTCCTGGAAGAT-GGTGAT-3Ј (reverse primer; Sigma-Aldrich), and 2 L of 1:100-diluted template cDNA. Cycling settings were an initial denaturation step at 95°C for 8 min and 45 cycles of 95°C for 6 s, 60°C for 5 s, and 72°C for 15 s, followed by melting curve analysis to evaluate the specificity of PCR products. To ensure amplification of the appropriately sized fragment, PCR products were analyzed by electrophoresis in 3% agarose gels. PCR controls included a separate reaction in which either cDNA template or the reverse transcriptase was eliminated. None of these controls showed detectable amplification product (data not shown). GAPDH mRNA detection was estimated by use of the crossing point (CP), defined by the LightCycler software (Ver. 3.5) as the cycle at which each reaction reaches the logarithmic portion of the PCR curve. PCR determinations in each sample were performed in triplicate. To improve our results, we analyzed the ADM (NM_001124), and IL-8 (NM_ 000584) genes, which are known to quickly change expression in response to technical influences such as temperature. The PCR conditions for these reactions are shown in Table 1 Technical Briefs of the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem. org/content/vol51/issue7/.
Statistical analysis was performed with StatView software (Ver. 5; SAS Institute Inc.). Differences in mean RNA concentration or CP value according to either anticoagulant (EDTA, heparin) or lysis buffer (E, R, Q, and S) were estimated by paired Student t-test. Variation of RNA stability according to different storage times was calculated by the Friedman test. Values are reported as the mean (SE). A P value Յ0.05 was considered statistically significant.
As determined by trypan-blue counting, PBMC viability was 97.5 (1.3)%. According to results obtained with May-Grunwald-Giemsa staining, PBMC populations usually contained Ͼ97% mononuclear cells. To compare the purity and yield of total RNA obtained from the whole-blood collection under the conditions being investigated, we performed spectrometric analysis on the RNA samples extracted at t 0 . Regardless of the cell lysis buffer used, we observed no difference in the A 260 /A 280 ratio between anticoagulants [1.95 (0.12) and 1.94 (0.11) for EDTA and heparin, respectively; P ϭ 0.24], suggesting that RNA purity was equivalent for all samples. In contrast, the yield of total RNA at t 0 was higher in EDTA-blood than in heparin-blood: 23.9 (15.2) vs 19.1 (10.5) ng/L (P Ͻ0.0001; Fig. 1A ). The CP value of the GAPDH gene determined by real-time PCR indicated that RNA integrity was better in EDTA-blood than in heparin-blood (Fig. 1A in the online Data Supplement). The measured mean CP was 38.0 (2.0) cycles in EDTAblood and 40.4 (2.3) cycles in heparin-blood (P Ͻ0.0001; n ϭ 24). Melting curve analysis confirmed the presence of a single GAPDH-specific amplicon for all samples (data not shown). These results indicate that the use of EDTA as anticoagulant in blood collection ensures the best total RNA yield and quality. This conclusion was further supported by other findings involving blood-based RNA assays (10, 11 ) .
To further improve the yield of total RNA, we tested 4 different cell lysis buffers combined with automated MagNA Pure LC extraction. Typical results obtained for 12 donors at t 0 are shown in Fig. 1B and in Fig. 1B of the online Data Supplement. RNA concentrations were significantly higher with use of the E buffer than with the other buffers (P Ͻ0.01; Fig. 1B ). The RNA yield obtained in buffers Q and S did not differ significantly from the yield obtained in buffer R. Neither EDTA nor heparin affected this result (Fig. 1B) . In addition, RNA integrity was best in EDTA-blood with buffer E (Fig. 1B of the online Data Supplement). Results were similar for the ADM and IL-8 genes (panels A and B, respectively, of Fig.  2 of the online Data Supplement). We therefore propose that buffer E rather than buffer R be used to constitute PBMC banks for the purpose of RNA expression analysis. Impact of anticoagulants (EDTA and heparin; n ϭ 48 for both anticoagulants; A), cell lysis buffers (Eurogentec, Roche, Qiagen, and Stratagene; n ϭ 12 for all groups; B), and storage time (3, 5, 10 , and 15 months; n ϭ 8 for all time points) in Eurogentec buffer (EDTA-blood; C) on RNA concentration. The RNA concentrations in all panels are in ng/L. The results are shown as box-plots with medians (lines inside boxes), 25th and 75th percentiles (limits of boxes), and the 10th and 90th percentiles (whiskers). The F in panel A indicate outliers. NS, not significant.
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Finally, to determine whether buffer E would preserve the RNA of PBMCs over time, we analyzed total RNA obtained from 8 individuals at t 3 , t 5 , t 10 , and t 15 of PBMC storage time with reference to their t 0 values. For all samples examined, RNA purity, determined by the A 260 / A 280 ratio, was 1.8 -2.1, indicating that highly pure RNA could be obtained with storage in buffer E. In addition, for all 3 genes, we observed no significant variations in either the amount ( Fig. 1C ; Friedman test, P ϭ 0.0812) or the integrity (Fig. 1C of the online Data Supplement; Friedman test, P ϭ 0.3682) of RNA at t 3 , t 5 , t 10 , and t 15 compared with t 0 . Thus, buffer E provides advantageous conditions for PBMC storage at Ϫ80°C. In addition, it is noteworthy that buffer E is also suitable for manual extraction (see the manufacturer's instructions), which does not necessarily require specific and costly automation.
The kinetics of gene expression and RNA stability in blood samples processed ex vivo (preanalytical variables) are currently under intense investigation (6, 12, 13 ) . To guarantee optimal conditions, samples reach our laboratory for processing after a transportation time of Ͻ2 h at 4°C. Indeed, gene expression was shown to change 2 h after blood collection (13 ) , probably because of significant stress responses (12 ) or possible contact activation of cells in the collection tubes (9 ) . These findings underscore the extreme sensitivity of blood cells to ex vivo handling. One study has suggested that EGTA is preferable to EDTA as an anticoagulant to prevent the irreversible loss of antigen-specific lymphoproliferative responses in instances in which unclotted blood may be stored for long periods (14 ) . Methods such as the PAXgene tube system or addition of acidic phenol and guanidine isothiocyanate have been proposed to stabilize blood cell gene expression after prolonged incubation of blood ex vivo, but new methods and protocols are needed (8, 12 ) .
Our studies demonstrate that PBMC RNA is stable over time (up to 15 months) when blood samples are collected into EDTA tubes and when PBMCs are stored at Ϫ80°C in buffer E. We provide here a simple assay for rapid, efficient, and standardized banking of PBMCs, a key step in large gene expression studies. To our knowledge, this is the first comprehensive report on RNA stability over 15 months. Moreover, preliminary observations suggest that our protocol provides successful results in gene expression assays such as quantitative reverse transcription-PCR or microarrays (data not shown). Finally, our recommendations may be helpful for clinicians and researchers involved in experimentation with PBMC transcriptomes in molecular medicine and epidemiologic surveillance, an emerging field of noninvasive health applications. This work was supported by an INSERM Grant CRB "Collection de Ressources Biologiques" 4CH07H. We thank G. Siest, the staff of the Centre of Preventive Medicine of Vandoeuvre-lès-Nancy, France, and the participants who made this study possible.
X-linked recessive pattern resulting from mutations in the dystropin gene on Xp21. 1 . In approximately two-thirds of cases, the disease is inherited from female carriers, and the remaining cases come from de novo mutations in individuals without a family history of muscular dystrophy (2, 3 ) .
Approximately 60% of DMD cases are associated with large intragenic deletions of 1 or more exons in 2 hotspot regions in the proximal and central regions of the gene (exons 3-7 and exons 44 -55) (4 -8 ) . Approximately 6% of DMD mutations are associated with duplications of large segments (9 ) , and the remaining cases result from point mutations, small deletions, or insertions (10 -12 ) .
Affected males can be readily detected by the absence of an amplification product in a multiplex PCR, as described by Chamberlain et al. (13 ) and Beggs et al. (14 ) . Up to 98% of all frequent deletions can be detected, but in carriers, the nondeleted X chromosome hampers detection, making identification of DMD carrier status difficult. Several DMD carrier identification strategies based on quantitative Southern blotting (15 ) , fluorescent in situ hybridization (16 ) , linkage analysis (17 ) , fluorescencebased strategies, microchip electrophoresis, capillary electrophoresis (18 -27 ) , multiplex amplifiable probe hybridization (28 ) , and multiplex ligation-dependent probe amplification (29 ) have been described.
Denaturing HPLC (DHPLC) is a simple, rapid, non-gelbased, non-fluorescence-based method that uses ion-pair reversed-phase liquid chromatography for detection of DNA variations; the method is sensitive and specific (30 ). We describe a new application combining DHPLC with multiplex PCR to efficiently and accurately identify carrier and noncarrier status in DMD families.
We analyzed 84 DNA samples from the National Taiwan University Hospital, including DNA from 11 patients with dystropin gene deletions previously detected by gel electrophoresis, 1 patient with a duplication detected by the multiplex PCR/DHPLC detection method and confirmed by quantitative real-time PCR (27 ) , 23 obligate carriers and noncarriers from families with DMD patients, and 50 unaffected females from the general population. Genomic DNA was collected from peripheral whole blood by use of a Puregene DNA Isolation Kit (Gentra Systems) according to the manufacturer's instructions.
To amplify the dystropin gene, multiplex PCRs of the dystropin gene were carried out as described in Chamberlain et al. (13 ) and Beggs et al. (14 ) . The reaction described by Beggs et al. (14 ) uses multiplex I (exons 3, 50, 6, and 60) and multiplex II [muscle promoter (pm), exons 43, 13, 47, and 52]. The reaction described by Chamberlain et al. (13 ) uses multiplex III (exons 48, 17, 8, 44 , and 46) and multiplex IV (exons 45, 19, 51, 12, and 4).
Each multiplex PCR for the specific DNA fragments was performed in a total volume of 50 L containing 200 ng of genomic DNA, 0.04 -0.4 M each primer, 200 M deoxynucleotide triphosphates, 1 U of AmpliTaq Gold enzyme (PE Applied Biosystems), and 5 L of GeneAmp 10ϫ buffer II [10 mM Tris-HCl (pH 8.3), 50 mM KCl] in 2 mM MgCl 2 as provided by the manufacturer. Because amplification efficiencies differed among primer pairs in multiplex PCR, different amounts of the primers were used to obtain comparable signals within different exons. PCR amplification was performed on an MBS thermocycler (ThermoHybaid) with an initial denaturation step at 95°C for 10 min followed by 24 cycles of denaturation at 94°C for 1 min, annealing at 59°C for 1 min, and extension at 72°C for 3 min, with a final extension step at 72°C for 10 min.
For multiplex detection, we loaded 40 L of crude PCR product on a DNASep column (Transgenomic) and conducted DHPLC analysis in a WAVE DHPLC instrument (Transgenomic) as described previously (30 ). The initial and final concentrations of solvent B in the 12-min gradient were 46% and 70%, the flow rate was 0.9 mL/min, and the temperature was 50°C.
For each sample, we measured the heights and the areas of the different peaks from each exon, using the WAVE MAKER software, which labeled the data automatically. To identify female carrier status, as indicated by the presence of large deletions or duplications in the gene dosage analysis, the copy number of a specific test exon in the unknown samples was determined by the formula:
Copy number ϭ Peak height (area) of test exon (U)/ Peak height (area) of reference exon (U)
Peak height (area) of test exon (C)/ Peak height (area) of reference exon (C) ϫ 2 where U indicates the unknown sample and C the control sample. The reference exon is an undeleted or unduplicated exon in the same multiplex group as a deleted or duplicated/test exon.
We determined the linearity of the PCR reaction by testing the relationships among the number of PCR cycles (22-28 cycles) , the DNA concentration (50 -400 ng), and the amount of PCR product (31 ), and then standardizing the number of quantitative PCR reaction cycles to 24 cycles with a DNA concentration of 200 ng.
Using this technique to detect common exon deletions in the dystropin gene, we assigned 19 DNA fragments to 4 sets of multiplex PCR reactions according to their sizes and amplification efficiencies. To detect gene deletions, we analyzed the PCR products by both gel electrophoresis and DHPLC (Fig. 1 in the Data Supplement that accompanies the online version of this Technical Brief at http:// www.clinchem.org/content/vol51/issue7/). Deleted exons are indicated by the absence of corresponding signals in the affected cases compared with controls.
The results of multiplex PCR/DHPLC analysis of affected males, carriers, and noncarriers from different DMD families are shown in Fig. 1 . All results were analyzed by use of the ratios of deleted and undeleted exons. Every sample was analyzed at least 3 times, and the results were reproducible. Individuals were identified with decreased amplification of signals that were absent in affected individuals with deleted exons. In family C, no Clinical Chemistry 51, No. 7, 2005 dosage change is apparent in the mother; therefore, de novo mutation can be deduced. In family D, more than 1 exon deletion exists in the same multiplex PCR reaction.
In this situation, carrier state can still be correctly identified by calculating the ratios of tested exons to reference exons. Family A, affected male and the carrier individual (his mother) with deleted exons 48 -52; Family B, affected male and the carrier individual (his mother) with deleted exon 51; Family C, affected male with deleted exons 50 -52 and his noncarrier mother; Family D, affected male and the carrier individual (his mother) with deleted exons 45-60; E, affected male with duplicated exons 12-19. 
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Measured copy numbers of the dystropin gene from carriers, noncarriers, and unaffected females, obtained by multiplex PCR/DHPLC analysis and expressed in testexon to reference-exon ratios, are shown in Fig. 2 of the online Data Supplement. The measured copy numbers between deleted and undeleted exons can be differentiated unambiguously with the use of this analytical tool, enabling successful identification of unaffected females (Table 1 of the online Data Supplement). In our study, the peak height and peak area for PCR amplification results from each exon were divided by the reference exon, and the ratios of the unknown samples were compared with the control samples to determine the copy number of each exon. Theoretically, the copy number should be 1 for a single copy and 2 for a double copy. The mean values measured by peak height and peak area for a single and double copy are shown in Table 1 of the online Data Supplement. The values never overlapped in our controls. Large deletions in all of the DMD carriers were clearly identified with the multiplex PCR/DHPLC assay. Furthermore, 1 study patient with gene duplications was identified (Fig. 1) . Recently, a similar strategy was used to detect RB1 gene rearrangement (32 ).
Unlike other available techniques, including capillary gel electrophoresis, multiplex amplifiable probe hybridization, and multiplex ligation-dependent probe amplification, the multiplex PCR/DHPLC assay uses ultraviolet detection and automated instruments that can speed up carrier detection without the use of radioisotopes or fluorescence-labeled or gel-based materials. For clinical applications, a specific advantage of this detection system is the procedure for interpreting carrier status. Another advantage is that the crude PCR products do not require further purification before DHPLC analysis. Our method took ϳ3 h for PCR amplification and ϳ48 min for DHPLC analysis for 4 multiplex sets. The DHPLC analysis cost was less than US $4.00 for each sample. This technique thus is well suited for routine diagnostics.
In conclusion, the multiplex PCR/DHPLC detection system is a simple, rapid, and powerful assay enabling direct detection of deletions and duplications in DMD patients and carriers. This system may also be adapted for diagnostic use in other genetic diseases involving deletion and duplication mutations. This work was supported by grants from the National Science Council of Taiwan (NSC 93-2314-B-002-067).
Congenital analbuminemia is a rare autosomal recessive disorder characterized by the absence or very low concentrations of serum albumin (HSA) (1 ) . The disorder is conventionally defined as an HSA Ͻ1 g/L (as determined by immunoassay) associated with normal liver function and absence of protein loss (2 ) . The incidence of congenital analbuminemia is estimated to be Ͻ1 in 1 million births, without sex or race predilection. To date, 39 cases of congenital analbuminemia have been reported, 16 of which were diagnosed in children (3 ) . Despite multiple functions of HSA (4 ) , its absence is a relatively tolerable condition. Except for associated hyperlipidemia, minor edema, and mild fatigability, analbuminemic individuals suffer few adverse symptoms (3, 5, 6 ) . Such relative mildness of symptoms is attributed to a compensatory increase in hepatic biosynthesis of other plasma proteins (7, 8 ) .
Congenital analbuminemia is attributable to defects in the gene coding for HSA. The HSA gene is located on chromosome 4 and is split into 15 exons by 14 intervening introns (9 ) . The identification of multiple mutations that cause analbuminemia clearly indicates that it is a genetically heterogeneous disorder. Six of these mutations introduced stop codons (10 -13 ) , and 2 caused splicing defects and determined a premature termination of the translation (14, 15 ) . All were found to be present in the homozygous state. In the present study we characterized another case of congenital analbuminemia caused by 2 newly identified mutations in an Italian family.
The proband was a 29-year-old Italian man with an HSA of 10 -12 mg/L as determined by immunoassay. His medical history has been reported elsewhere (16, 17 ) . The proband's relatives had HSA concentrations in the lower end of the reference interval (father, 35 g/L; mother, 33 g/L; sister, 42 g/L). All gave informed consent before participating in the study. We used single-strand conformation polymorphism analysis to screen the coding region of the HSA gene in samples from the proband and a control individual. Briefly, the 14 exons and their intron-exon junctions were PCR-amplified from genomic DNAs by use of specific primer pairs as already reported (10 ) . After amplification, 2 L of PCR products was mixed with 8 L of singlestrand conformation polymorphism analysis buffer containing 950 mL/L formamide, 10 mmol/L NaOH, and 0.5 g/L of both xylene cyanol and bromphenol blue. The mixtures were denatured at 95°C for 3 min and chilled on ice before electrophoretic separation. Denatured and nondenatured samples were then loaded on a 1ϫ Mutation Detection Enhancement gel (FMC BioProducts) and visualized with silver staining. No abnormal bands were detected in the proband sample, except in exon 13. Direct sequencing of this fragment revealed a silent C-to-T substitution at nucleotide 15229. This variation, which introduced a recognition site for the restriction enzyme SacI (New England Biolabs), was demonstrated by restriction fragment length polymorphism (RFLP) analysis to be a common single-nucleotide polymorphism in samples from 50 control individuals (allele frequency, 0.585).
We next investigated the 14 PCR products by direct sequencing. Both strands were sequenced with the fluorescent dideoxy termination method (BigDye Terminator Cycle Sequencing Kit, Ver. 3.1; Applied Biosystems) on an ABI 310 automated sequencer according to the manufacturer's protocol (Applied Biosystems). Electropherograms were analyzed with the ABI Prism 310 Data Collector software. The first mutation was identified in exon 10 and consisted of a C3 T transition at nucleotide 11999 (Fig. 1A) . This mutation changes codon CAG for Gln-385 to stop codon TAG (Gln385Stop). The putative protein product should have a length of 384 amino acid residues. The proband was heterozygous for the defect as demonstrated by the sequencing electrophoretogram (Fig. 1A) . As this mutation abolished a restriction site for the BseMII enzyme (MBI Fermentas), we used RFLP analysis to evaluate its segregation in the proband's family. As shown in Fig. 1B , the digestion pattern revealed the presence of an abnormal 340-bp fragment in the proband and his father, whereas the mother and the proband's sister were normal. This confirmed that the proband was heterozygous for Gln385Stop and demonstrated that he inherited this mutation from his father. The Gln385Stop mutation was named Roma2, for the city of origin of the father. This mutation was not found in 50 DNA samples obtained from healthy individuals.
We were unable to evaluate whether the putative truncated protein produced by the Roma2 allele was present in serum. In all previous cases with a stop codon 1256 Technical Briefs within an exon, no evidence was found for the presence in the serum of the truncated albumin form.
The second mutation was found in exon 11. The penultimate nucleotide of exon 11 had undergone an A3 G transition at position 13378 (Fig. 1C) . This mutation changes the codon TAT for Tyr-452 to codon TGT (see Fig. 1A of the Data Supplement that accompanies the online version of this Technical Brief at http://www. clinchem.org/content/vol51/issue7/). This mutation was also confirmed by restriction analysis using the HpyCH4 III enzyme (New England Biolabs). We found that it was inherited from the mother (Fig. 1D) . We named this mutation Fondi for the small town in Central Italy where she was born.
As the GT dinucleotide is known to be a site for intron splicing, we predicted that the Fondi mutation introduced a novel, anticipated donor splicing site replacing the first 2 bases of intron 12. To confirm this hypothesis, we examined HSA cDNA obtained from proband's leukocytes. Briefly, total RNA was extracted with use of TRIzol (Invitrogen) according to the manufacturer's protocol. The RNA was reverse-transcribed by use of MultiScribe reverse transcriptase (Applied Biosystems) with random hexamers to obtain total cDNA. The primer pair 5Ј-ATTGTGAGCAAAAAGAGCAGCTTG-3Ј (forward) and 5Ј-TTTTGTTGCCTTGGGCTTGTGTTT-3Ј (reverse) was designed from mRNA sequences in GenBank by use of Primer3. We used this pair of primers, spanning exon 10 Clinical Chemistry 51, No. 7, 2005 to exon 13, to PCR-amplify the region of HSA cDNA where the mutation was located. All reactions were performed on a T Personal (Biometra) thermocycler in a 20-L reaction volume. Amplified products were then sequenced using the reported primers as described above. The cDNA electropherogram from the proband showed a double sequence starting from nucleotide 13378, a finding that indicates the presence of both wild-type and mutated alleles (see Fig. 1B of the online Data Supplement). These results confirmed that the mutation disrupts the normal codon TAT for Tyr-452, leaving the residual T nucleotide to join the first 2 CT nucleotides of exon 12 (see Fig. 1A of the online Data Supplement). This effect leads to a reading frameshift that introduces a premature stop codon 12 amino acids downstream in exon 12 (see Fig. 1A of the online Data Supplement). The translation product from the Fondi allele is expected to be a truncated protein consisting of 463 instead of the 585 amino acid residues usually found in mature HSA.
In previously reported cases of analbuminemia attributable to aberrant splicing, the consequences of the defect at the mRNA level were not evaluated (13, 14 ) . We were able to obtain the mutated HSA mRNA from circulating leukocytes and thus directly confirmed that the Fondi allele caused a defect in the ligation of exon 11-exon 12 sequences. How aberrant splicing of the HSA gene affects mRNA processing is poorly known. Studies on Nagase analbuminemic rats, with a splicing error in the HSA gene (18, 19 ) , demonstrated a marked decrease in hepatic mRNA (20 ) . Although we were unable to measure the specific amount of mutated mRNA in our study participants, a substantial amount of cDNA was obtained by reverse transcription-PCR from our proband's leukocytes, suggesting that the Fondi allele did not cause, at least in leukocytes, a complete degradation of the mutant mRNA.
In summary, we report the first case of congenital analbuminemia attributable to compound heterozygosity for 2 new mutations in the HSA gene. We also demonstrated that circulating leukocytes may be used to investigate the effects of analbuminemia-causing mutations on mRNA processing, making it possible to reevaluate all analbuminemic patients in whom molecular characterization of the HSA gene was carried out only at the genomic level. Secreted predominantly from the stomach (1 ), ghrelin is a peptide identified in 1999 as an endogenous ligand of the growth hormone (GH) secretagogue receptor located on the pituitary gland, thus fulfilling the criteria of a braingut peptide (2, 3 ) . The brain-gut axis serves as an effector of anabolism by regulating growth, feeding, and metabolism via vagal afferent-mediating ghrelin signaling (2, 4 ) . The role of ghrelin as a brain-gut peptide emphasizes the significance of afferent vagal fibers as a major pathway to the brain, serving the purpose of maintaining physiologic homeostasis (2, 4 ) . The importance of ghrelin as a "hunger hormone" with orexigenic effects mediated by the hypothalamic peptides, agouti-related peptide, and neuropeptide Y, and the fact that it is the most potent peripheral signal of diminishing energy stores, implies that ghrelin release might be the most important of the 1258 Technical Briefs many redundant mechanisms ensuring human survival in times of famine (4 ) . However, the wide tissue distribution of ghrelin suggests that it may have other functions as well (5 ) . Further characterization of the functions of ghrelin is fundamental to discovering new approaches to the diagnosis and treatment of different disease entities, including those related to the catabolic response to surgical trauma (2 ) . In this preliminary study, we report the pattern of ghrelin secretion in different perioperative periods in patients undergoing elective cholecystectomy.
Circulating Ghrelin in Patients Undergoing
Thirty patients [17 females; age range, 20 -45 years; body mass index (BMI), 18 -25 kg/m 2 ] with ultrasoundconfirmed cholecystolithiasis undergoing elective cholecystectomy via laparoscopy or laparotomy at the Surgical Department at the Hospital Umberto I°of Rome were recruited to the study. All patients presented a low surgical risk (American Society of Anesthetists' score 1 or 2). Patients with a diagnosis of choledocholitiasis, jaundice, acute cholecystitis, and pancreatitis; those with a history of metabolic, endocrine, hepatic, cardiac, or renal disease; those who, before surgery, received medication known to interfere with hormonal responses to stress; and those with a history of tobacco use or substance abuse were not eligible for the study. The study was approved by the Hospital Ethical Committee, and each participant gave informed consent to be included in the study.
After an overnight fast, between 0830 and 0900 in the morning, 20 study patients , thiopental (5 mg/kg), and vecuronium (0.08 mg/kg). Anesthesia was maintained with 1% sevoflurane in a mixture of 60% nitrous oxide and 40% oxygen and intravenous fentanyl and vecuronium. Fluid replacement was performed with normal saline solution during surgery (7 mL ⅐ kg Ϫ1 ⅐ h Ϫ1 ) and throughout the postoperative course (1 mL ⅐ kg Ϫ1 ⅐ h Ϫ1 ) until the next morning after surgery (see below) when the seventh blood sample was taken.
Blood samples were collected from each patient at ϳ60 min before induction of anesthesia (sampling time t 1 ); after induction of anesthesia (t 2 ); at 30 min intraoperatively (t 3 ); at the end of surgery, i.e., at exsufflation or incision closure (t 4 ); in the first postoperative hours [t 5 and t 6 : 6 h (afternoon) and 10 h (evening) after the start of surgery]; and on the morning (0800) of the first postoperative day (t 7 ). Serum concentrations of immunoreactive ghrelin were measured in duplicate with an RIA that recognizes both the acylated and des-acyl forms (Phoenix Pharmaceuticals; lower limit of detection, 10 ng/L; interand intraassay CVs, 9.0%-13.6% and 4.5%-5.3%, respectively, as reported by the manufacturer).
A frequency distribution of the 30 measured ghrelin concentrations at each of the 7 time points was constructed and inspected. Given that every frequency distribution was positively skewed, the natural logarithm of each observed value was calculated, and these logarithms were used in all subsequent calculations. To investigate how the mean ghrelin concentration changed between the first and the seventh and last observation, we applied 2-way ANOVA (in which the rows represented the patients and the columns were the 7 time points) to the logarithms of the ghrelin concentrations to determine whether there were significant differences between the mean concentrations at times t 1 to t 7 . We compared the differences between the observed values at times t 2 to t 7 with the baseline value (t 1 ) by paired t-test and used regression analysis to investigate whether the patients' sex and the type of operation influenced the mean logarithmic values of the ghrelin concentrations.
The 2-way ANOVA revealed highly significant (P Ͻ0.00005) differences between the mean values at times t 1 to t 7 . The geometric mean concentrations of ghrelin at sampling times t 1 to t 7 are shown in Table 1 . After induction of anesthesia, at t 2 , the geometric mean ghrelin concentrations decreased by 5%, but this difference was not statistically significant compared with baseline values. By time t 3 , ghrelin had decreased by 23% (P ϭ 0.035) compared with baseline values, and by time t 4 , the concentration had decreased by 30% (P ϭ 0.01), reaching a minimum at t 5 with a decrease of 39% (P Ͻ0.00005) compared with baseline values. At time t 6 , the concentrations had increased slightly, and by t 7 they had returned to baseline values.
In regression analysis, sex, duration of surgery, and type of surgical procedure had no significant effect on log ghrelin concentrations when adjusted for patients and times. To our knowledge, this is the first report on the characteristics of ghrelin secretion in different perioperative periods of a cohort of adult patients undergoing elective cholecystectomy. The novel finding of our study is that ghrelin may be added to the list of substances whose concentrations remain stable until after the induction of anesthesia, at time t 2 (6 ) . However, the finding of a significant decrease in ghrelin concentrations from baseline during the intraoperative period, as well as over the course of several hours after surgery, was somewhat surprising. In general, ghrelin concentrations are inversely correlated with positive energy balance, BMI, body fat mass, adipocyte size, and leptin concentrations (7) (8) (9) , whereas they are lower in obese persons than in controls (9 ) . Pima Indians, known for their propensity to develop type II diabetes and obesity, also have lower circulating ghrelin concentrations, independent of BMI, compared with matched controls (9 ) . Patients with anorexia nervosa have higher plasma ghrelin concentrations than age-and sex-matched controls, and weight gain lowers their increased ghrelin concentrations (10 ) . Thus, fluctuations in plasma ghrelin concentrations may reflect physiologic adaptation to long-term alterations in energy balance (4 ) .
Although ghrelin concentrations may increase in response to short-term fasting, the effects of a more prolonged fast on ghrelin have not been well characterized (11, 12 ) . Only a very few studies have evaluated ghrelin concentrations in humans who have fasted completely and therefore have lost the meal-related pattern. Using single measurements, Norrelund et al. (13 ) , in a study of healthy individuals and GH-deficient patients during a 36-h fast, found no significant changes in ghrelin concentrations in either group. In contrast, Muller et al. (14 ) reported that healthy nonobese individuals who fasted for 3 days developed a diurnal rhythm in ghrelin characterized by low concentrations in the morning with subsequent increases in the afternoon and at midnight. This study was, however, difficult to evaluate because a synthetic GH secretagogue was administered before and during fasting and plasma ghrelin was measured every 6 h in a relatively small number of individuals (n ϭ 10). Recently, Chan et al. (11 ) described the circadian profiles of ghrelin in healthy lean persons who had fasted for 72 h (n ϭ 6) and who had blood samples taken every 15 min for 24 h; the authors found minimal variation in ghrelin during the day before concentrations increased in the evening, followed by a significant decrease between 0200 and 0400. More recently, Espelund et al. (12 ) studied 33 healthy young adults (17 lean and 16 obese) with blood sampling every 3 h from 12 to 84 h of fasting. In contrast to the data from Chan et al. (11 ) , Espelund et al. (12 ) found that serum ghrelin showed a marked diurnal rhythm with a nadir in the morning (0800), maximum values in the afternoon, and a gradual decrease during the night. This pattern was preserved during the entire fasting period and was independent of sex and obesity.
Considering this background, the ghrelin kinetics observed in our clinical setting involving a combination of fasting and uncomplicated surgical injury were quite different from any of the above-mentioned ghrelin patterns observed in response to the metabolic stress of fasting by itself in healthy individuals. Patients who undergo elective cholecystectomy do not appear to follow the circadian meal-independent rhythm of ghrelin secretion. The ghrelin response to surgical injury may be interpreted as an appropriate adaptation to an acute stress to help maintain homeostasis (15 ) . Indeed, adaptation to starvation or caloric restriction may be the primary physiologic need for which ghrelin evolved as a peripheral regulator of energy balance (16, 17 ) . On the other hand, it may be an adaptive response to inflammation. Consistent with the latter possibility are the recent findings by Dixit et al. (18 ) in a murine model of lipopolysaccharide (LPS)-induced endotoxemia, a well-recognized model associated with anorexia resulting from excessive production of proinflammatory mediators and a refractory catabolic state. The authors demonstrated that ghrelin infusion in LPS-challenged mice leads to a significant inhibition of the proinflammatory cytokines in circulation as well as in various organs. They also demonstrated that LPS-induced inflammatory anorexia is also significantly reduced in ghrelin-treated mice. Their data complement those reported previously by Basa et al. (19 ) and Hataya et al. (20 ) in rats. Whereas Basa et al. (19 ) showed that LPS-induced endotoxemia leads to inhibition of ghrelin secretion, Hataya et al. (20 ) found that ghrelin infusion increases body weight in septic animals. Considering these data, it seems plausible that inhibition of ghrelin secretion after LPS challenge might exacerbate the ongoing inflammatory insult and promote the development of a catabolic state. Thus, the decrease in ghrelin that we have found in the present study may be associated with the transition from an inflammatory immune response to an adaptive immune response, and future studies of the prognostic role of ghrelin after elective and nonelective surgery, with and without a complicated postoperative course, are warranted.
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The finding of tumor-related mRNA (tyrosinase mRNA, telomerase component mRNA, various tumor-derived mRNAs, and viral RNAs) in plasma from a patient with cancer suggests that real-time quantitative reverse transcription-PCR (RT-PCR) study of circulating plasma mRNAs may be used as a very simple assay for residual tumor after surgery or therapy (1) (2) (3) .
Gestational trophoblastic diseases (GTDs) are a heterogeneous group of diseases that include partial and complete hydatidiform moles (CHMs), invasive moles, choriocarcinomas, placental site trophoblastic tumors, and epithelioid trophoblastic tumors. Human chorionic gonadotropin (hCG) is generally used as a tumor marker in the clinical management of all GTDs. Recently, hCG-␤ mRNA from placenta has been detected in maternal plasma by real-time quantitative RT-PCR (4 ), suggesting that this assay may be useful in the management of GTDs.
In this study, we measured plasma mRNA concentrations by real-time RT-PCR in 3 GTD patients with CHMs and 1 with choriocarcinoma.
Blood samples (10 mL) were collected before and after suction evacuation or chemotherapy. Plasma mRNA was extracted, and a 1-step real-time RT-PCR assay was performed as described by Ng et al. (4 ) . We selected hCG-␤ mRNA as a tumor marker of GTD and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as a housekeeping gene. Primer sets and TaqMan probes for the 2 genes selected were prepared as described previously (4 ). We prepared calibration curves for quantification of each mRNA by assaying serial dilutions of HPLC-purified single-strand synthetic DNA oligonucleotides from each PCR amplicon (R 2 ϭ 0.99; slope, Ϫ2.9 to 3.3). The absolute concentration of each mRNA is reported as copies/mL of maternal plasma, based on the formula described by Farina et al. (5 ) . Interpolation of obtained results on the calibration curves indicated that hCG-␤ mRNA concentrations ranged from 1 ϫ 10 7 to 1 ϫ 10 1 copies/mL, and GAPDH mRNA concentrations ranged from 1ϫ 10 10 to 1 ϫ 10 4 copies/mL. Each sample was analyzed in triplicate under thermal conditions as described previously (4 ) .
All study protocols were approved by the Committee for the Ethical Issues on Human Genome and Gene Analysis in Nagasaki University, and written informed consent was obtained from all of the women. None of the data regarding plasma mRNA concentrations influenced the clinical management of patients.
Three cases with CHM, diagnosed by pathology examinations, were treated twice with suction evacuation. Chest x-rays indicated no pulmonary lesion. The day of the first evacuation was called day 0, and the second evacuation was on day 7. The plasma hCG-␤ mRNA in all 3 cases decreased rapidly to undetectable (Ͻ10 copies/ mL) by day 7 (Fig. 1A) , and the corresponding hCG protein in serum, as measured by an IRMA, also decreased to Ͻ1000 IU/L until 35 days after the first evacuation ( Fig. 1B) (6 ) .
A patient with clinical choriocarcinoma, which was diagnosed by the diagnostic score used in Japan (6 ), showed a Ͻ3 cm pulmonary lesion detected by chest x-ray and a biphasic pattern of basal body temperature (BBT). Etoposide and actinomycin D therapy was given on days 0 -3, 15-18, 29 -32, and 43-46. Her plasma hCG-␤ mRNA concentration showed a decreasing tendency similar to the pattern for hCG protein in serum, but exhibited 
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The cases with CHM had no metastatic lesions, whereas the case with choriocarcinoma had lung metastasis. Rapid clearance of plasma hCG-␤ mRNA may reflect complete elimination of CHM, and the transiently increased concentration of plasma hCG-␤ mRNA after every each course of therapy may reflect apoptotic activity induced by the therapy (3, 7 ) .
The concentration of plasma GAPDH mRNA in all 3 cases with CHM also increased after both evacuations (Fig. 1C) , and that in a case with choriocarcinoma also increased after therapy with etoposide and actinomycin D ( Fig. 1E and Table 1 ). Thus, cell/tissue damage by both evacuations and chemotherapy may be associated with increased circulating concentrations of GAPDH mRNA (3, 7 ) .
Our results suggest that measurement of plasma mRNA by real-time quantitative RT-PCR can be used as a noninvasive diagnostic, prognostic, and follow-up test for GTD (1) (2) (3) . The mRNA is cleared rapidly and provides information different from that obtained with hCG immunoassays. The measurements may be particularly useful in patients whose serum contains substances (such as human anti-mouse antibodies) that interfere in immunoassays. As our data were based on only a few cases, it remains to be seen in additional studies whether the method is sensitive enough to monitor changes in mRNA concentrations in GTD. Chronic myeloid leukemia (CML) is a rare hematopoietic stem cell disorder characterized by the t(9;22) translocation. This somatic event leads to the formation of the BCR-ABL fusion gene, which is translated in a functional protein (1 ) . The Bcr-Abl oncoprotein differs from the endogenous c-Abl protein in both its subcellular localization and its tyrosine kinase (TK) activity. The deregulated Abl TK activity of the Bcr-Abl protein initiates the oncogenic process and represents a target to TK inhibitors.
Among a series of compounds exhibiting TK inhibition, STI 571 (imatinib) was found to be highly effective against Abl and its derivative Bcr-Abl (2, 3 ) . This molecule targets the inactive conformation of the kinase, which leads to stabilization of the protein in its inactive form and impairs ATP binding (4 ) . Approved for the treatment of CML, imatinib induces hematologic and cytogenetic remissions in the chronic phase as well as in the blast phase (5-7 ).
A significant proportion of patients, however, become resistant to the treatment. Different mechanisms of imatinib resistance have been described, in particular point mutations within the sequence of the BCR-ABL gene coding for the TK domain (8 -10 ) . Approximately 30 missense mutations have been identified in CML patients. Within the Bcr-Abl TK domain, these mutations are Clinical Chemistry 51, No. 7, 2005 located in the nucleotide binding loop (P-loop), in the active site (imatinib contact site), or in the activation loop (A-loop; Fig. 1A ). Among these mutations, some prevent the binding of imatinib, and others make this binding more difficult. In the latter case, a dose increase can overcome the resistance. Recently, a novel TK inhibitor was described (11 ) . In vitro, this molecule remains active for the majority of Bcr-Abl mutants, with the exception of T315I. Molecular monitoring of CML patients is based on the quantification of BCR-ABL transcripts in peripheral blood (or bone marrow) samples by real-time reverse transcription-PCR at regular intervals. It has recently been proposed that during imatinib therapy, a more than 2-fold increase in the BCR-ABL transcript concentration is a primary indicator for an emerging mutation within the Bcr-Abl kinase domain (12 ) .
Detection of mutations in the ABL TK domain of the BCR-ABL oncogene by several methods has been reported. Some of these focus on known mutations (e.g., allele-specific oligonucleotide PCR and PCR with restriction fragment length polymorphism analysis). Others, such as denaturing HPLC (13, 14 ) can identify unknown single-base mutations in a given sequence. We describe a mutation screening method based on double-gradientdenaturing-gradient gel electrophoresis (DG-DGGE) (15, 16 ) , which relies on wild-type (WT)/mutant heteroduplex formation. The entire BCR-ABL TK domain covers 4 exons of the ABL gene; therefore, the analysis was performed at the RNA level by means of 2 overlapping PCR fragments (5Ј and 3Ј in Fig. 1A ). DG-DGGE is generally performed on the ABL sequence by a single-step PCR. In this case, both BCR-ABL and ABL tyrosine kinase domains were amplified. Nested PCR was used when the analysis was restricted to BCR-ABL.
Total RNA was extracted from blood or bone marrow samples with RNABle reagent (Eurobio) according to the manufacturer's instructions. RNA pellets were resuspended in 40 L of RNase-free water. cDNA was synthesized from 1 g of total RNA in a 20-L reaction mixture by use of Moloney murine leukemia virus reverse transcriptase (Invitrogen).
For a nested PCR analysis, 2 L of cDNA was subjected to a first round of PCR (25 cycles) with the forward primer located in exon 13 of the BCR gene (5Ј-ACAGCATTC-CGCTGACCATC-3Ј) and the reverse primer located in exon 8 of the ABL gene (5Ј-GAACGGTCAATTCCCGGG-3Ј) under the following conditions: denaturation at 95°C for 15 min, followed by 25 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 90 s. Amplifications were carried out in 50 L with 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl 2 , 200 M each deoxynucleotide triphosphate, 0.5 M each primer, and 2.5 U of Sure Prime DNA polymerase (Q-Biogene).
An aliquot of the first PCR product (5 L of a 1:100 dilution) or 5 L of cDNA (in the case of a single-step PCR) was used for the ABL TK amplification. For this purpose, 2 pairs of primers, 5F (5Ј-CTGTCTATGGTGTGTC-CCCC-3Ј) and 5R [5Ј-(40GC)-GCAGTTTCGGGCAGCAA-GAT-3Ј] and 3F (5Ј-AAAGAGATCAAACACCCTAACC-3Ј) and 3R [5Ј-(40GC)-TCCCAAAGCAATACTCCAAATG-3Ј] were designed using the MELT94 program (http://web-.mit.edu/osp/www/melt.html). A 40-base GC-rich fragment (40GC; 5Ј-GCCCGCCGTCCCGGCCCGACCCCCG-CGCGTCCGGCGCCCG-3Ј) was added to the 5Ј end of each Amplifications were carried out as described above. The heteroduplexes were generated during the last cycles of PCR. DG-DGGE analysis was performed on a DGGE-2001 system (CBS Scientific). An aliquot (15 L) of PCR sample was electrophoresed in a colinearly increasing double gradient of 50% to 95% denaturant (100% denaturant: 7 mol/L urea, 400 mL/L formamide) and 6.5% to 12% polyacrylamide (acrylamide/bisacrylamide, 37.5/1). Electrophoresis was performed in 1ϫ Tris-acetate-EDTA buffer (40 mmol/L Tris-acetate, 20 mmol/L sodium acetate, 1 mmol/L EDTA, pH 8.0) at 1800 V-h (e.g., 15 h at 120 V) and at a constant temperature of 60°C. Gels were stained with ethidium bromide and visualized through ultraviolet transillumination.
In the presence of a shift in the acrylamide gel, the nucleotide change was characterized by direct sequencing of the PCR product carried out in both directions, using the BigDye Terminator (Ver. 1.1) Cycle Sequencing Kit and the ABI PRISM 310 sequencer (Applied Biosystems) according to the manufacturer's recommendations. To avoid false-negative results, PCR products that showed no mobility shift in DG-DGGE were mixed with an equal amount of WT amplicon, denatured (5 min at 95°C), annealed to form heteroduplexes (15 min at 56°C), and analyzed again.
To evaluate the efficiency of the DG-DGGE methods, we analyzed cDNA samples from patients carrying mutations in the BCR-ABL TK domain that had already been characterized by direct sequencing. Compared with the WT controls, all samples showed an abnormal DGGE pattern ( Fig. 1 , B and C). In the presence of a mutation, up to 4 bands were visualized: the WT homoduplex, the mutant homoduplex, and the 2 heteroduplexes (M244V, G250E, E255K, Y253H, M351T, T315I, F317L, and V379I). In these cases, the difference in the intensities of the homoduplex bands reflected the ratio between mutated and WT sequences. In a few samples (Q252E, Q252H, and H396P), the 2 homoduplexes were not separated. A double mutant with a dominant (E255V) and a minority mutation (Y253H) was detected by DG-DGGE. The E255V mutation, but not the minority mutation, was identified by direct sequencing of the corresponding PCR product. The 2 faint bands of high molecular weight were excised from the gel, purified, and amplified for direct sequencing. The 2 mutations (E255V and Y253H) were then characterized. To confirm these results, amplified products from E255V and Y253H mutants were mixed and subjected to DG-DGGE. Three homoduplexes (Y253H, E255V, and WT) and 5 bands corresponding to the WT/ Y253H, WT/E255V, and Y253H/E255V heteroduplexes were clearly distinguishable in this assay. Thus, all previously identified mutations were unambiguously detected within the entire ABL TK domain.
Different point mutations leading to amino acid substitution were detected in 26 of 59 imatinib-resistant CML patients (M351T in 6; M244V and T315I in 4; G250E in 3; Q252E in 2; and Q252H, Y253H, E255K, E255V, F317L, V379I, and H396P in 1 each).
To define the detection threshold of the method, we serially diluted cDNAs carrying the M244V, E255K, or T315I mutations to concentrations ranging from 50% to 1% in a WT cDNA (Fig. 1D) . The heteroduplex bands remained clearly detectable until the 5% (M244V and T315I) or the 2% dilution (E255K). Mutated sequences can thus be detected when they account for at least 5% of total cDNA.
When correctly designed and applied, the percentage of point mutations detectable by DGGE is theoretically 100% in a given sequence. The method described here appears to be robust, inexpensive, and sensitive enough to detect a small proportion of mutant with an excess of WT sequences. Moreover, the detection of minority mutations is possible.
Screening of the entire TK domain of the BCR-ABL gene enables the classification of imatinib-resistant CML patients into 3 groups based on the amino acid change. The first group consists of patients for whom an imatinib dose increase can overcome the resistance (e.g., M244V and F359V mutants). The second group includes patients with a permanent resistance to imatinib (e.g., G250E, E255V, and H396P mutants); they could benefit from secondgeneration TK inhibitors. Finally, CML patients carrying the T315I mutation (found in 15%-20% of imatinib-resistant cases) seem to show a universal resistance toward all known TK inhibitors. Alternative treatments are currently in evaluation for patients carrying this mutation. Thus, a screening procedure such as DG-DGGE can be used to ensure the best therapeutic strategy as targeted therapies are developed for diseases such as CML. Endothelial-cell-derived nitric oxide (NO) relaxes vascular smooth muscle cells, causes vasodilation, and inhibits platelet aggregation. It has been demonstrated that NO 3 is the predominant and stable form of NO present in plasma and represents the bioavailability of NO (1, 2 ) . NO generation is depressed in blood vessels affected by atherosclerosis, and a loss of NO activity is associated with impaired vasoreactivity, enhanced platelet aggregation, and increased endothelial cell-leukocyte interactions (3 ) .
Recently, evidence has accumulated that suggests that increased concentrations of the amino acid homocysteine (Hcy) also increase the risk for cardiovascular disease (CVD) (4 ). Hcy concentrations can be lowered by supplementation with folate, vitamin B 6 , vitamin B 2 , and vitamin B 12 (5, 6 ) . In particular, folate may also contribute in the prevention of CVD because folate seems to restore impaired NO metabolism (7 ) .
In the present investigation, we included apparently healthy persons. Individuals on all types of medications were excluded from this cross-sectional study. Blood samples were collected from participants who had been fasting for 12 h. The blood samples were centrifuged at 4°C within 1 h and stored at Ϫ80°C until analysis. Informed written consent was obtained from all participants. The study was approved by the Regional Ethics committee, University of Bergen, Norway.
Total homocysteine (tHcy) concentrations in plasma were measured by an HPLC method (8 ) . Plasma NO 3 concentrations were measured by capillary electrophoresis (9 ), and total serum cholesterol, HDL-cholesterol, and serum triglyceride concentrations were measured by a routine enzymatic colorimetric method (Roche/Hitachi). The concentrations of erythrocyte folate, serum folate, and vitamin B 12 were measured on an Access Immuno Assay System (Sanofi Pasteur Diagnostics).
The program "Power and Precision" was used for the power calculations. Power computations were performed for the comparison of smokers vs nonsmokers with serum folate as the primary endpoint, based on a 2-sample t-test for ln-transformed data. All P values given are 2-tailed. The statistical program StatView for the Macintosh (Abacus Concepts) was used for all calculations.
The characteristics of the study participants are given in Table 1 . In a simple regression analysis, we found a significant positive relationship between the concentra- 
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Technical Briefs tions of serum folate and plasma NO 3 (R ϭ 0.17; P ϭ 0.017) and a significant inverse relationship between the concentrations of serum folate and tHcy (R ϭ 0.244; P ϭ 0.0005). In a multiple regression analysis that included age, sex, body mass index, NO 3 , tHcy, and vitamin B 12 as independent variables and serum folate as dependent variable, we found a significant positive relationship between the concentrations of serum folate and plasma NO 3 (P ϭ 0.0037), and a significant negative relationship between the concentrations of serum folate and tHcy (P ϭ 0.0005; Table 1B of the Data Supplement that accompanies the online version of this Technical Brief at http:// www.clinchem.org/content/vol51/issue7/). The present findings may indicate that folate is involved in the intracellular formation and release of NO into plasma. There are at least 2 mechanisms by which NO could be converted to NO 3 . The first possibility is the direct and rapid oxidative conversion of NO to NO 3 in the presence of oxy-hemoproteins in the extracellular fluids. The second possibility is that the oxidation of NO to NO 3 takes place through the formation of an NO 2 intermediate, also in the presence of oxy-hemoproteins (10 ). 5-Methyltetrahydrofolate (5-MTHF) is the principal form (perhaps as much as ϳ95%) of folate in serum; therefore, most studies have used serum folate as an appropriate marker for folate status in their aim to explore the relationship between serum folate and tHcy concentrations (11 ) . As suggested in Fig. 1 , 5-MTHF is related to the formation of both NO and Hcy in the cell. In the presence of 5-MTHF, the enzyme dihydrobiopterin reductase can reduce quininoid dihydrobiopterin to tetrahydrobiopterin (BH4) (12 ). 5-MTHF also stabilizes BH4, enhances its binding to NO synthase (NOS), increases the activity of NOS, and thus regulates the ratio of NO to superoxide (O 2 . ) (13 ) In a recent study it was suggested that folic acid supplementation improves endothelial function in coronary artery disease (CAD) by a mechanism largely independent of Hcy (16 ) . It is reasonable to assume that the improvement in endothelial function was attributable to increased formation of NO during the folic acid intervention. A different study showed that folic acid restored endothelial dysfunction in patients with hypercholester- olemia who had tHcy concentrations within the reference interval (17 ) .
Our observation that smokers have higher plasma concentrations of NO 3 than do nonsmokers is in accordance with previously published data (Fig. 1B of the online Data Supplement) (18 ) , but are contradictory to the findings of Node et al. (19 ) . Oxidants, free radicals, and trace elements in cigarette smoke may activate macrophages and neutrophils in the circulation, which may generate increased amounts of NO and nitrite (20 ) . It is also possible that cigarette smoke may prevent reaction of NO with thiols to form nitrosothiols, important reservoirs for NO in blood (21 ) .
From Nitric oxide (NO) is essential in numerous physiologic processes and may be involved in related pathologic processes. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of isoforms of NO synthase in humans (1 ) . ADMA originates from protein arginine methylation by protein arginine methyltransferases after protein hydrolysis (2 ) . Enzymatic hydrolysis by dimethylarginine dimethylaminohydrolases to dimethylamine and citrulline is the major pathway for elimination of ADMA (3 ). Circulating ADMA is altered in patients with cardiovascular and neurologic diseases, erectile dysfunction, and many other disorders (4 -6 ) , and increased circulating ADMA independently predicts future cardiovascular events and mortality (7, 8 ) . Short-time infusion of ADMA affects hemodynamics and cardiac function in humans (3, 9 ) .
Analytical methods for the measurement of ADMA include HPLC, capillary electrophoresis, ELISA, and mass spectrometry (MS). The commonly used HPLC methods with fluorescence detection (10 ) measure o-phthaldialdehyde derivatives of ADMA. These derivatives are not stable and must be analyzed on-line. Moreover, ADMA must be separated by chromatographic means from its biologically inactive isomer, symmetric dimethylamine 1268 Technical Briefs (SDMA). Thus, these HPLC methods have long analysis times of up to 45 min. Alternatively, ADMA and SDMA can be analyzed by gas chromatography-mass spectrometry (11, 12 ) , which shows different fragmentation patterns for the respective ions. These methods include several extraction and derivatization steps and require considerable analysis times. Recently, Kirchherr and Kü hn-Velten (13 ) developed a mass spectrometric method that omits derivatization procedures; however, chromatographic separation of ADMA from SDMA is still required for this method. Here we report a simple and rapid liquid chromatography-tandem MS (LC-MS/MS)-based method with 1 derivatization step and sample pretreatment consisting of protein precipitation. This is the first LC-MS-based method that separates methylated arginine derivatives by specific fragmentation patterns instead of by chromatographic separation.
Analyses
. The mobile phases consisted of methanol containing 1 mL/L formic acid (mobile phase A) and water containing 1 mL/L formic acid (mobile phase B). Chromatography was performed at 25°C with a flow rate of 0.4 mL/min. The gradient started with 2% A for 0.5 min and increased linearly to 50% A over 1.5 min, with subsequent reequilibration with 2% A for 2 min. Nitrogen was used as the nebulizing and drying gas (380°C) at 90 and 180 L/h, respectively.
For ionization in the positive electrospray ionization mode (ESIϩ), the needle and shield voltages were set at 5850 and 400 V, respectively. The following transitions were observed after fragmentation with argon (1. ϩ for authentic ADMA and SDMA, respectively. The m/z 228 and m/z 214 ions were absent in the product ion mass spectra of ADMA and SDMA, respectively. We checked ion suppression by comparing peak areas of aqueous calibrator solutions without matrix and calibrator added to plasma matrix (15 ) . Ion suppression was Ͻ10% for 5 different specimens.
We used 3 different calibrators, l-arginine, ADMA, and SDMA, at 6 different concentrations (n ϭ 5 each): 0, 25, 50, 100, 250, and 500 mol/L for l-arginine and 0, 0.25, 0.5, 1, 2, and 4 mol/L for ADMA and SDMA, respectively. Aqueous stock solutions of l-arginine, ADMA, and SDMA were made by weighing authentic material supplied by the manufacturer. The calibrators were treated exactly the same as patient plasma samples. ]-ADMA) corresponding to concentrations of 50 and 2 mol/L, respectively, in 50 L of biological sample. Subsequently, proteins were precipitated with 100 L of acetone, and dried supernatants were derivatized. Compounds were derivatized with 100 L of 1 mol/L HCl in 1-butanol for 17 min at 65°C. After evaporation, samples were reconstituted in 1 mL of water; 20 L of the water extract was injected on the column. The mean (SD) retention times of the butyl ester derivatives of l-arginine, ADMA, and SDMA, respectively, were 1.03 (0.04) min (CV ϭ 3.9%; n ϭ 6), 1.84 (0.02) min (CV ϭ 1.3%), and 2.03 (0.02) min (CV ϭ 0.8%). Differences in retention times for unlabeled and labeled compounds were not statistically significant. The linear regression equations for peak-area ratio (LC-MS/MS; y) and ratio of injected calibrators (x) were as follows: y ϭ 0.94x Ϫ 0.001 (r 2 ϭ 0.999) for l-arginine; y ϭ 0.98x ϩ 0.02 (r 2 ϭ 0.999) for ADMA; and y ϭ 2.05x ϩ 0.01 (r 2 ϭ 0.999) for SDMA. Ideally, regression analysis of peak-area ratios should give a slope of 1; however, the intensities of the daughter ions obtained for labeled and unlabeled compounds were not the same. Thus, only under MS conditions was a slope of 1 obtained: The linear regression equations for peak-area ratio (LC-MS; y) and ratio of injected calibrators (x) were as follows: y ϭ 1.003x Ϫ 0.02 (r 2 ϭ 0.999) for l-arginine; y ϭ 1.001x ϩ 0.01 (r 2 ϭ 0.999) for ADMA; and y ϭ 1.002x ϩ 0.03 (r 2 ϭ 0.998) for SDMA. Nevertheless, calibration curves were calculated to account for these differences, and the slopes of the calibration curves were included in all plasma concentration calculations. The lower limits of detection, defined as a signal-to-noise ratio of 3, were 45 nmol/L for l-arginine, 3 nmol/L for ADMA, and 2 nmol/L for SDMA.
We validated our LC-MS/MS method by adding different concentrations of l-arginine, ADMA, and SDMA in quintuplicate to samples. l-Arginine was added at 0, 0. Table 1 . The observed recoveries of the added analytes were 97.7%-111% for l-arginine, 96.9%-105% for ADMA, and 90.8%-109% for SDMA. All CVs were Ͻ6% for the imprecision and Ͻ20% for recovery except for the addition of 0.5 mol/L larginine. Thus, the analytical range of the method was 1-250 mol/L for l-arginine and 50 nmol/L to 4 mol/L for ADMA and SDMA, with 1 mol/L and 50 nmol/L representing the lower limits of quantification for l- 
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Technical Briefs arginine and ADMA and SDMA, respectively. The addition of l-arginine, ADMA, or SDMA did not influence the measurement of the other analytes. We also determined within-and between-run imprecision (CVs; n ϭ 10). The within-run CVs were 3.3% for l-arginine, 2.6% for ADMA, and 2.5% for SDMA. Between-run CVs were 4.7% for l-arginine, 4.1% for ADMA, and 3.9% for SDMA We also measured ADMA in plasma samples from healthy human volunteers (n ϭ 22) by this LC-MS/MS method. Shown in Fig. 1 is a typical chromatogram of a human plasma sample. Samples were aliquoted (50 L) and frozen at Ϫ20°C before analysis. The mean (SD) concentrations of l-arginine, ADMA, and SDMA were 65.6 (23.4), 0.55 (0.14), and 0.69 (0.23) mol/L, respectively. The mean (SD) molar ratio of l-arginine to ADMA was 132 (55).
Our LC-MS/MS-based method allows for the simultaneous determination of ADMA, SDMA, and l-arginine and has been validated for the measurement of these 3 analytes in human plasma. Values obtained for l-arginine, ADMA, and SDMA in human plasma are within previously reported ranges (11) (12) (13) 16 ) . Major advantages over previous reported methods for the measurement of ADMA include a minimized sample volume and reduction in laboratory work. In particular, in comparison with other LC-MS-based methods (13, 14, 16, 17 ) , sample run time has been reduced to 4 min including reequilibration. Chromatographic separation required only slightly more than 2 min. This considerable reduction in analysis time was achieved by use of the specific fragmentation patterns of the ester derivatives of ADMA and SDMA. Identical MS spectra were obtained from the ester derivatives of ADMA and SDMA, but the major fragments in the daughter ion spectra for ADMA and SDMA were at m/z 214 and m/z 228, respectively. These ions were specific for ADMA and SDMA: they were absent in the corresponding spectra of SDMA and ADMA, respectively. In contrast to previous reports, the proposed method allows, for the first time, spectrometric instead of chromatographic separation of these methylated arginines (see the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/ vol51/issue7/). When a fetus is subjected to a massive perinatal hypoxicischemic insult, it may suffer sufficient damage to cause intrauterine death and stillbirth (1) (2) (3) (4) (5) . In less severe, 6 -8 ) . Hypoxia during labor leads to anaerobic respiration in the fetus and an accumulation of lactic acid in the tissues, producing metabolic acidosis. Damage to the brain and heart in asphyxia neonatorum is not a direct result of hypoxia, but rather of the toxic effects of reactive oxygen species generated after reperfusion of ischemic tissues. We have demonstrated that lipid peroxidation in the fetus increases during normal labor (9 ) and that umbilical cord plasma lipid peroxide concentrations are higher in situations known to lead to intrapartum hypoxia (10 -12 ) and much lower after elective cesarean delivery (13 ) . Reperfusion of damaged organs with oxygenated blood after delivery may also be detrimental to the infant's long-term survival.
Relationship between Isoprostane Concentrations

Clinical Chemistry
Prediction of long-term neurodevelopmental outcomes in infants with birth asphyxia remains challenging. Unfortunately, previous studies have shown that clinical and biochemical variables, such as umbilical artery blood gases or Apgar scores, are of limited value in predicting morbid neonatal outcome. We have proposed the use of lipid peroxidation products, acting as footprints of oxidative stress, as alternative measures of perinatal outcome (14 ) . Increased concentrations of lipid peroxidation products in cord arterial blood are associated with clinical situations known to cause fetal distress, but they have not been shown to be associated with significant morbid outcomes such as HIE. This study aims to demonstrate an association between increased umbilical cord blood lipid peroxide concentrations and morbid neonatal outcomes. The study hypotheses are (a) that cord arterial plasma isoprostane (15 ) concentrations are higher in neonates who require immediate admission to the neonatal intensive care unit (NICU) for respiratory support than in healthy neonates, and (b) that cord arterial plasma isoprostane concentrations are higher in infants who will ultimately develop HIE than in those who will recover without neurologic sequelae.
In total, 301 neonates had cord blood 8-isoprostane measured, and 297 cord blood samples were confirmed as arterial in origin (see the Materials and Methods section of the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/ content/vol51/issue7/). Of the infants for whom arterial cord blood samples were available, 13.1% (39 of 297) required immediate postdelivery admission to a NICU for respiratory support, and another neonate (1 of 297; 0.3%) died immediately after birth and was classified as a fresh stillbirth. Of these 40 (39 ϩ 1) cases, 24 (60%) were originally classified as having asphyxia neonatorum, with 11 of the 24 (45.8%) ultimately classified as having poor outcome [8 with HIE and 3 with postnatal death (PND)]; the remaining 13 cases (54.2%) were classified as having a The horizontal line is the 90th centile of the cord arterial isoprostane concentration; the vertical line is the 10th centile for cord arterial base excess. Perinatal outcomes: v, prematurity only; ࡗ, perinatal death; , poor outcome (asphyxia at birth); Ⅺ, sepsis (no asphyxia at birth); ‚, good outcome (asphyxia at birth); ✕, good outcome (no asphyxia); --, lowess regression for the total sample. (Fig. 1 of the online Data Supplement), and in the post hoc analysis comparing cord isoprostane in NICU cases that developed HIE with those that did not. Shown in Fig. 1 is a scatter plot of cord arterial blood 8-isoprostane plotted against cord arterial base excess according to actual neonatal outcome group for all cases. Lowess regression suggested a linear relationship between 8-isoprostane concentrations and base excess when base excess was below Ϫ10. Linear regression analysis of this group (n ϭ 23) gave a correlation coefficient (r) of Ϫ0.673 (P ϭ 0.002).
The results of ROC curve analysis for predictions of poor outcome (HIE/PND) on the basis of 1-and 5-min Apgar score, cord arterial blood isoprostane concentration, cord arterial pH, and cord arterial base excess are shown in Table 1 . The values for the 40 cases admitted to a NICU for respiratory support are listed first, followed by the values for all 297 cases. All infants who survived with evidence of significant brain damage (HIE) had severe metabolic acidosis (base excess Ϫ12 or lower), as did one of the infants who subsequently died. The pattern of oxidative stress was similar, with 6 of these 9 cases (66.7%) having increased 8-isoprostane concentrations. The 8-isoprostane concentration was also increased in 25 nonasphyxiated cases (9.2%); 17 (68%) of these had nuchal cord entanglement detected at birth, with 12 (48%) having tight nuchal entanglement.
Although the significant difference in isoprostane concentrations between healthy infants and neonates requiring NICU admission for respiratory support is of interest, an ability to identify those infants who will ultimately develop HIE or PND from among sick infants requiring NICU admission would be of greater value. In a post hoc analysis of the 39 infants admitted to a NICU for respiratory support, cord arterial isoprostane concentrations were shown to be significantly higher (P Ͻ0.01) in neonates who subsequently were classified as having a poor outcome.
The 8-isoprostane concentration performed significantly better than chance (area under the curve, 0.74), roughly on a par with cord arterial pH and 5-min Apgar score, but it significantly underperformed compared with base excess (DeLong statistic, P Ͻ0.05). The 1-min Apgar score was not able to differentiate between infants who were later classified as HIE/PND and those with a good outcome. Isoprostane exhibited only a moderate ability to identify those infants with a poor outcome from among all neonates studied (area under the curve, 0.70), but it underperformed compared with the standard outcome measures (pH, base excess, and 1-and 5-min Apgar scores). This reflects the wider variance in 8-isoprostane concentrations among apparently healthy neonates, particularly when there has been evidence of cord compression during labor. Base excess appears to be a better predictor of HIE, suggesting that the duration of sublethal hypoxic insult, as well as its severity, plays an important role in the pathophysiology of HIE. The prediction of poor outcome cannot be improved by combining isoprostane with base excess because all 8 cases of HIE had base excess measurements between Ϫ12 and Ϫ20.
For those neonates with metabolic acidosis, cord arterial blood isoprostane concentrations and base excess showed a linear relationship, suggesting that oxidative stress plays a role in a significant proportion of cases with hypoxic-ischemic encephalopathy. Only 1 of the 3 perinatal deaths had a base excess in this range. This suggests that the other 2 perinatal deaths were unrelated to chronic intrapartum hypoxia. In fact, one was a fresh stillbirth associated with a massive placental abruption, and the other was a neonatal death attributable to chorioamnionitis but with no evidence of fetal distress or asphyxia at birth (Apgar scores of 9 at 1 min and 10 at 5 min). It is not surprising, therefore, to find that these 2 cases also had 8-isoprostane concentrations within the reference interval. Despite the presence of metabolic acidosis in the pooroutcome group, only 2 cases actually had a cord arterial blood pH Ͻ7.05 (1 stillbirth and 1 case with HIE). One healthy neonate also had a low pH and base excess of Ϫ12.
The links between obstetric complications, intrapartum fetal heart rate abnormalities, and perinatal outcome measures are tenuous, partly because of the therapeutic effect of intervention on outcome measurements (treatment paradox) (16 ) . Obstetric intervention may remove the cause of fetal distress but does not necessarily represent an abrupt end to the pathologic processes. Unlike pH, which can be affected by intra-and postpartum resuscitation, lipid peroxide concentrations remain relatively stable immediately after delivery and may actually continue to increase after resuscitation if the hypoxic injury has been severe (17 ) .
In the pathogenesis of perinatal HIE, variable degrees of hypoxia occur over a period of several hours, usually during labor. During this time, the fetus compensates for the production of excess lactic acid by producing buffering hydrogen ions, causing an increase in base deficit: the pH therefore remains within the reference interval until these buffering systems decompensate. Similarly, excess oxygen free radicals are removed by various circulating and tissue antioxidants, causing depletion of total antioxidant capacity; evidence of oxidative stress (increased lipid peroxidation) manifests only after these antioxidant systems decompensate. Whether these 2 systems are damaged by recurrent asphyxia to an equal extent and Clinical Chemistry 51, No. 7, 2005 during the same time frame is beyond the scope of this observational study.
Our study highlights the fact that isoprostane concentrations have the same limitations as other measures of obstetric outcome, such as pH and Apgar score: i.e., they are increased in neonates with HIE, but may also be increased in apparently healthy infants and may be within reference values in infants who die from acute causes or in whom a pathology manifests after delivery.
We are grateful to all medical and nursing staffs in the labor wards and neonatal units at The clinical relevance of B-type natriuretic peptide (BNP) as a diagnostic tool and prognostic marker in patients with cardiovascular diseases has been confirmed recently (1-3 ) . Over the last 5 years, several immunoassay methods for the measurement of BNP, which share some analytical characteristics, such as full automation, turnaround time Ͻ60 min, lower imprecision, and/or better analytical and functional sensitivity, have become commercially available (1, 4 ) . The analytical performance and diagnostic accuracy of immunoassays for BNP were compared recently (5, 6 ) . In the present study, we evaluated the analytical performance and diagnostic accuracy of an automated immunochemiluminescent assay for BNP (ACCESS System; Beckman Coulter). We also compared its performance and accuracy with the TRIAGE BNP test (Biosite). The 2 immunoassays use as antigen the intact BNP 1-32 peptide and the same mouse anti-human BNP antibodies. The capture antibody (Scios) recognizes the peptide ring, whereas the detection antibody (Biosite) recognizes an epitope between amino acids 5 and 10 at the NH 2 terminus (6, 7 ). All statistical analyses were performed by use of parametric tests after log transformation of the original data. Nonparametric tests were also performed and showed identical statistical trends.
We collected blood samples from 91 healthy individuals [51 women and 40 men; mean (SD) age, 43.2 (13.4) years; range, 16 -71 years] and 214 patients with idiopathic or secondary cardiomyopathy (only 21 with a left ventricular ejection fraction Ͼ50%). Blood was collected between 0800 and 0900 after the individuals had fasted overnight and had rested for 20 min in a supine position. Immediately after withdrawal, blood samples (8 -10 mL) were placed in ice-chilled disposable polypropylene tubes containing EDTA (1 mg/mL of plasma). Plasma samples were obtained shortly after venipuncture by centrifugation for 15 min at 4°C and then were frozen and stored at Ϫ20°C in 0.5-mL aliquots until being assayed.
We found that plasma samples can be kept at 37°C for We assessed the detection limit of the ACCESS by repeatedly measuring (n ϭ 20) the calibrator with a BNP concentration of 0 ng/L in 3 different runs. The mean (SD) measured concentration was 0.3 (0.1) ng/L (range, 0.3-0.4 ng/L). We confirmed the results of a previous study from our laboratory indicating that the detection limit of the TRIAGE is Ͻ8 ng/L (manufacturer-reported detection limit, 5 ng/L) (8 ) . The imprecision profiles of the TRIAGE and ACCESS, obtained by repeated measurements over 20 different days of several plasma samples (7 on the TRIAGE and 12 on the ACCESS) with BNP concentrations covering the analytical working range, are shown in Fig.  1A . According to the IFCC goals for desirable (15% total CV) and optimum (10% total CV) imprecision (7 ), the 2 methods had similar functional sensitivities (ϳ10 ng/L and 30 ng/L, respectively). The imprecision for samples with BNP values Ͻ10 ng/L was not satisfactory in either method. We assessed the within-run and total imprecision of the ACCESS according to the NCCLS EP5-A guideline (including experimental protocol, number of measurements, and data calculation) (9 ) by repeatedly assaying 2 plasma samples with BNP concentrations of 52.6 and 1095 ng/L in duplicate on 20 different working days (both in the morning and in the afternoon). For the 2 samples, within-run imprecision was 3.4% and 1.6%, respectively, and total imprecision was 8.4% and 5.9%.
After exclusion by statistical analysis of the 17 samples with BNP values Ͻ5 ng/L in the TRIAGE assay, we found a close linear relationship (R ϭ 0.919; n ϭ 287) between the 2 methods: ACCESS ϭ 62.5 (14.1) ϩ 0.932 (0.024) TRIAGE (P Ͻ0.0001 for both). The Bland-Altman plot of the same data confirmed that there was a difference between the values measured with the 2 immunoassays; this difference increased proportionally as the measured concentration increased (Fig. 1B) (10 ) . There was a slight but significant mean difference between the values [mean (SD) difference for TRIAGE Ϫ ACCESS, Ϫ45.2 (217.8) ng/L (minimummaximum, Ϫ1152 to 1667 ng/L; P Ͻ0.0001); mean % difference, Ϫ0.2% (minimum-maximum, Ϫ2.0% to 1.7%)].
All 91 healthy persons were nonobese, normotensive, and free from acute or chronic diseases. Moreover, all had values within the reference intervals for creatinine, urea, glucose, uric acid, albumin, electrolytes, cardiac markers, and hemoglobin as well as for erythrocyte and leukocyte To evaluate the diagnostic accuracy of the 2 methods, we measured only samples from the 193 patients with a clinically ascertained diagnosis of heart failure. The clinical characteristics of these patients are reported in Table 1 . Cardiac morphology and function were assessed by 2-dimensional echocardiography, or cardiac catheterization when needed. The median (range) ACCESS and TRIAGE BNP concentrations measured were 171 (2-4833) ng/L and 118 (Ͻ5 to 4930) ng/L, respectively. The distributions of BNP values measured by the 2 methods in these patients grouped according to the severity of heart failure [New York Heart Association (NYHA) functional classes I to IV] are shown in Figs. 1 and 2 of the online Data Supplement. However, the results obtained with both the TRIAGE and ACCESS indicated a significant difference between the mean BNP values in healthy persons vs heart failure patients (P Ͻ0.0001 by Scheffè test after ANOVA).
We used ROC curve analysis to evaluate the diagnostic accuracy of the 2 methods in differentiating between healthy persons and patients with heart failure. We found no difference in diagnostic accuracy between the 2 methods for differentiating healthy persons from patients with mild (NYHA class I and II; n ϭ 122; P ϭ 0.196) or severe (NYHA class III and IV; n ϭ 71; P ϭ 0.697) heart failure. For the TRIAGE, the areas under the curves were 0.840 (SE, 0.027; 95% CI, 0.788 -0.893) for patients with mild disease and 0.998 (SE, 0.002; 95% CI, 0.995-1.000) for patients with severe heart failure, whereas for the ACCESS system, the areas under the curves were 0.870 (SE, 0.023; 95% CI, 0.825-0.916) for patients with mild disease and 0.997 (SE, 0.002; 95% CI, 0.993-1.000) for patients with severe heart failure. The BNP values corresponding to a sensitivity of 95% in differentiating healthy persons from patients with mild heart failure were 7.5 ng/L (corresponding specificity, 40%) for the ACCESS and 5.1 ng/L for the TRIAGE (corresponding specificity, 29%). The BNP values corresponding to a specificity of 95% were 41 ng/L (corresponding sensitivity, 65%) for the ACCESS and 29 ng/L (corresponding sensitivity, 63%) for the TRIAGE (Fig. 3 of the online Data Supplement). However, it is important to emphasize that the 95% sensitivity with the TRIAGE was obtained at a cutoff near the assay detection limit. The decision cutoff values from the current study are strictly related to our specific clinical setting, comparing healthy persons and patients with clinically ascertained heart failure. In routine clinical practice, several groups of individuals/patients suspected of having a specific disease are usually compared.
The present data confirm and extend previous results suggesting that BNP results are method dependent and that a single predefined common cutoff value cannot be used (5, 6) . Furthermore, we demonstrated that immunoassays that use the same antibodies and calibration materials do not automatically give the same results. However, the cutoff and reference values of these 2 methods are similar. (2, 3 ) . Before the sixth week of gestation, ITA appears to be the predominant form of hCG (2) (3) (4) . In Down syndrome pregnancies, differentiation of the cytotrophoblast into a syncytiotrophoblast may be delayed, leading to increased production of ITA (5 ) .
Invasive
Urinary ITA is a promising candidate for use as a biochemical marker in Down syndrome screening. In one study conducted during the second trimester of pregnancy, ITA alone detected 78% of the Down syndrome cases at a 5% false-positive rate (6, 7 ) . In a setting that simulated routine use, urinary ITA was reported to be the best single marker in the second trimester (8 ) . In the first trimester of pregnancy, however, the performance of urinary ITA is lower, with a reported 63% Down syndrome detection rate at a 10% false-positive rate (9 ) .
ITA is detectable in serum as well as in urine (10 ). Studies have not been performed with serum ITA because of concerns about the stability of ITA in serum, possible loss of ITA when blood is collected in gel barrier tubes, and possible aggregation. A recently developed automated immunochemiluminometric assay measures ITA in various sample types, including serum (11 ) . In the present study, we investigated the Down syndrome screening performance of serum ITA before 12 weeks of gestation and compared it with the performance of pregnancyassociated plasma protein A (PAPP-A) and free ␤-subunit in the same sample set.
Sera from 24 women with Down syndrome-affected pregnancies and 320 unaffected pregnant women were used in this retrospective study. Samples were collected from women at 9 weeks and 5 days (9 ϩ 5) of gestation to 11 weeks and 4 days (11 ϩ 4). These samples were collected between 1999 and 2002, with permission, before chorionic villus sampling. The primary indication for chorionic villus sampling was advanced maternal age (Ն36 years). All samples were collected at the Antenatal Diagnosis Unit of the University Hospital Groningen, The Netherlands, into non-gel-barrier Vacutainer Tubes. An Institutional Review Board-approved protocol was followed. Control samples were matched for gestational age, maternal age, and length of storage. The mean gestational age was 76.4 days for cases and 76.0 days for controls. The mean (SD) maternal age was 38.8 (2.36) years for cases and 37.2 (3.04) years for controls. The median duration of sample storage was 2 years and 1 month for cases and 2 years and 2 months for controls. Blood samples were allowed to clot for 1-3 h at room temperature and were centrifuged at 2500g and 10°C for 10 min. Serum fractions were frozen immediately and stored at Ϫ20°C and never thawed at room temperature except before being assayed. Serum samples were then thawed overnight at 4°C and analyzed within 4 h.
ITA was measured by an immunochemiluminometric assay on the Nichols Advantage ® platform (Nichols Institute Diagnostics) with an acridinium-ester-labeled, antihCG␤ monoclonal antibody (B207) and a biotinylated ITA-specific monoclonal capture antibody (B152) (11 ) . The assay has a calibration range up to 300 g/L, with automatic dilution at higher concentrations. The assay has Ͻ1% cross-reactivity with recombinant hCG (11 ) . The reported intra-and interassay variations (as CV) are Ͻ8% and 12%, respectively.
PAPP-A and free ␤-subunit were both measured by a fluoroimmunoassay (AutoDELFIA ® PAPP-A and Free hCG␤ reagent sets; Perkin-Elmer). The detection limits of the assays are 5 mIU/L for PAPP-A and 0.2 g/L for free ␤-subunit. The intra-and interassay variations (CVs) for PAPP-A were Ͻ2% and 4%, respectively, at a concentration of 1500 mIU/L. For free ␤-subunit, the CVs were Ͻ4% and Ͻ5% at 40 g/L.
We used STATISTICA for Windows, Ver. 6 (StatSoft Inc). Multivariate discriminant analysis was performed to calculate the risks. The multiples of the median (MoM) were derived from regressed medians, with gestational days used as the independent variable. All parametric statistical procedures were based on the natural logarithms of the concentrations or MoM values. A Monte Carlo model was applied to adapt detection and falsepositive rates to the present age-standardized population of The Netherlands. Each patient was assigned the mean of 10 randomized maternal age-related risks where the randomization was based on the proportion of maternal age rates according to the present birth frequencies in The Netherlands.
Means, SD values based on logarithmic MoM values, and median MoM values for all 3 markers are summarized in Table 1 .
The squared Mahalanobis distance was 1.42 for ITA, 1.73 for free ␤-subunit, and 2.50 for PAPP-A.
The predicted detection rates for Down syndrome for the combination of ITA and PAPP-A at 3%, 5%, and 10% false-positive rates were 62%, 71%, and 83%, respectively. For the combination of free ␤-subunit and PAPP-A, the predicted detection rates were 58%, 75%, and 79%, respectively. The associations among ITA, PAPP-A, and free ␤-subunit concentrations were calculated in both affected and control pregnancies. In controls, there was a significant correlation between ITA and free ␤-subunit. The Pearson correlation coefficients (r) between the log-transformed MoM values were as follows: ITA/free ␤-subunit, 0.63; ITA/PAPP-A, 0.15; and PAPP-A/free ␤-subunit, 0.27.
The ROC curves for both ITA and free ␤-subunit in combination with PAPP-A, including maternal age after modeling against the age-standardized population of The Netherlands in 2002 (12 ) , are shown in Fig. 1 . From these curves, the predicted detection rate for a given screenpositive rate can be determined.
We have shown that serum ITA is a useful firsttrimester marker for Down syndrome screening. In the present study the combination of PAPP-A and ITA detected 71% of the Down syndrome cases at a 5% falsepositive rate. The predicted detection rate for the combination PAPP-A/ITA, including maternal age after modeling against the age-standardized population of The Netherlands, was 63% at a 5% false-positive rate (Fig. 1) .
PAPP-A was the most powerful biochemical marker in this study, as evidenced by the highest Mahalanobis distance. Although the median MoM value in Down syndrome cases was slightly higher for ITA (2.6 MoM) than for free ␤-subunit (2.2 MoM), ITA was not a better marker than free ␤-subunit, perhaps because there was less variation in free ␤-subunit concentrations in the control population (see the SDs in Table 1 ). The higher Mahalanobis distance for free ␤-subunit (1.7) compared with ITA (1.4) indicates that free ␤-subunit was a slightly better marker in this study.
The ROC curves (Fig. 1) indicate that at false-positive rates of 2%-7.5%, the PAPP-A/free ␤-subunit combination outperforms the PAPP-A/ITA combination, whereas at false-positive rates Ͻ2% and between 7.5% and 10%, the PAPP-A/ITA combination performed better.
Because the gestational age window in the present study was only 2 weeks (9 ϩ 5 to 11 ϩ 4) and the sample size was small, we do not know whether ITA is a better marker than free ␤-subunit during the very early first trimester (ϳ9 weeks of gestation). In late first trimester (12-14 weeks of gestation), serum ITA might be a better marker than free ␤-subunit because urinary ITA concentrations in affected pregnancies have been shown to be very high at those gestational ages (13 ) . Moreover, because the correlation between ITA and PAPP-A is less than that of free ␤-subunit and ITA (i.e., ITA is more independent of PAPP-A), an ITA/PAPP-A combination may be a more effective screen than the free ␤-subunit/ PAPP-A combination.
ITA should not be added as a third marker (i.e., added to free ␤-subunit and PAPP-A) because of the high correlation between ITA and free ␤-subunit in unaffected pregnancies.
The results of this study are comparable to the early first-trimester (10 -11 weeks of gestation) study of ITA in maternal urine samples (9 ) . Because urinary ITA studies during the second trimester of pregnancy show a greater discriminatory power (i.e., 78% detection at 5% falsepositive rate) (6, 7 ) , it is expected that serum ITA will also have a higher Down syndrome detection rate in the second trimester. Currently, studies are in progress to establish the role of ITA in the second trimester of pregnancy as a serum marker for Down syndrome. The recently identified apolipoprotein A-V gene (APOA5) has been shown to play an important role in hypertriglyceridemia (1 ). Genetic variation in APOA5 has been consistently associated with plasma triglyceride concentrations in several studies (2) (3) (4) . Moreover, some studies have demonstrated additional associations with lipoprotein subclasses, remnant-like particles, and cardiovascular disease risk (4 -6 ) . Several single-nucleotide polymorphisms (SNPs) in the human APOA5 gene have been detected with differing frequencies depending on the population analyzed (7, 8 ) , and Klos et al. (7 ) have also suggested context-dependent associations in different populations. Overall, 5 common SNPs, Ϫ1131TϾC, Ϫ3AϾG, 56CϾG, IVS3 ϩ 476GϾA, and 1259TϾC, have been widely reported. Apart from the 56CϾG SNP, the other SNPs are in strong linkage dysequilibrium, producing 3 haplotypes (11111, 22122, and 11211) representing ϳ98% of the population in Caucasians (5, 9 ) ; therefore, 2 independent APOA5 SNPs (56CϾG and Ϫ1131TϾC) can be analyzed in association studies as indicators of the corresponding haplotypes. The former consists of a nonsynonymous substitution, changing codon 19 from serine to tryptophan (S19W), whereas the latter is a T-to-C substitution 1131 nucleotides upstream of the initiation codon. To date, in most published reports, these SNPs have been genotyped by PCR with restriction fragment length polymorphism (RFLP) analysis (3 ) .
A system for high-throughput genotyping using fluorescence melting curve analysis, the LightTyper TM (Roche), has recently become commercially available. This instrument (10 ) offers higher throughput than the original LightCycler TM (11 ) . The LightTyper is designed explicitly for melting curve analysis to perform rapid, straightforward, reliable allelic discrimination. The system, which uses 384-well plates, provides postamplification genotyping within 10 -15 min and performs genotyping automatically. A variety of probe chemistries are compatible for genotyping, including single-labeled probes and fluorescence resonance energy transfer probes (10 ) . SimpleProbes TM are designed to specifically hybridize to a target sequence that contains the SNP of interest (12 ) . Once hybridized, the SimpleProbe emits a larger fluorescent signal than when it is not hybridized to its target sequence. SimpleProbes are more cost-effective than fluorescence resonance energy transfer probes and represent a major advance in decreasing the cost and complexity of SNP analysis (12 ) . We report here the validation of an assay based on the LightTyper system and SimpleProbes to rapidly screen for the 56CϾG and Ϫ1131TϾC SNPs in the APOA5 gene.
In the validation study we genotyped 825 randomly selected individuals (age range, 18 -75 years) from the Spanish Mediterranean population. All participants gave informed consent, and the study protocol was approved by the Ethics Committee of the School of Medicine of the University of Valencia.
DNA, isolated from blood, was first genotyped for the 56CϾG SNP in the APOA5 gene by melting curve analysis with the LightTyper; the results were then compared with those obtained with the classic RFLP method. For the melting curve analysis, a 136-bp fragment containing the 56CϾG SNP was amplified with primers 5Ј-AGAGC-CCAGGCCCTGATTA-3Ј and 5Ј-CATCTTCTGCTGATG-GATCTGCT-3Ј (TIB MOLBIOL) together with the SimpleProbe Flq-TCTCCACAGCGTTTTCGGCC-p (TIB MOLBIOL), where Flq represents a fluorescence quencher. PCR was carried out in 384-well plates with a total volume of 10 L per well in a Thermocycler (Mastercycler-ep380 ® ; Eppendorf). The reaction mixture used in the PCR consisted of 40 ng of genomic DNA, 0.2 L of each primer (10 M), 1 L of the SimpleProbe (1.6 M), 5 U of Fast Start Taq Polymerase (Roche Diagnostics GmbH), 1.2 L of 25 mM MgCl 2 , and 200 M each deoxynucleotide triphosphate (Roche Diagnostics). After an initial denaturation at 94°C, 34 PCR cycles were performed with 30 s of denaturation at 94°C, 45 s of annealing at 55°C, and 45 s of extension at 72°C; final extension was at 72°C for 10 min. A final melting cycle was performed on the LightTyper by heating to 85°C and cooling to 40°C at a ramping rate of 0.2°C/s, with fluorescence data collected continuously. The assay exploits the thermal properties of DNA, i.e., the melting temperature (T m ). We designed the probe to match the wild-type DNA (56C allele), so that the wild-type DNA is 100% complementary to the fluorescent probe, making this complex more stable and thus giving it a higher T m (65.5°C). The presence of the mutation gives a lower T m (56°C). This difference in T m allows genotypes to be assigned. The fluorescence signal (F) is plotted in real time against the temperature (T) to generate melting curves for Clinical Chemistry 51, No. 7, 2005 each sample. From these curves, melting peaks (Fig. 1) are generated by plotting the negative derivative of F with respect to T against T (ϪdF/dT against T) (13 ) . The melting peak for homozygous CC samples occurs at a higher temperature than the melting peak for homozygous GG samples. In CG heterozygotes, both temperature peaks can be detected.
The genotyping results for the 825 individuals from the Mediterranean population are shown in Table 1 . To validate these results, we subsequently determined the 
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Technical Briefs 56CϾG polymorphism in these 825 individuals by RFLP analysis. PCR was carried out in a total volume of 25 L in the same thermocycler under standard conditions. The following forward and reverse primers were used for amplification (3 ): 5Ј-GGCTCTTCTTTCAGGTGGGTCT-CCG-3Ј and 5Ј-GCCTTTCCGTGCCTGGGTGGT-3Ј (TIB MOLBIOL). This amplification was designed to force a GϾA (T in the reverse primer, shown underlined), which introduced a TaqI restriction site in the rare allele (3 ). After restriction enzyme digestion with TaqI (Promega) at 65°C for 2 h, the common C allele gave fragments of 134 and 23 bp, whereas the G allele gave a single 157-bp product. The fragments were separated by electrophoresis on a 4% Metaphor ® agarose gel. The PCR conditions consisted of initial denaturing at 96°C for 5 min, followed by 30 cycles at 96°C for 30 s, 63°C for 30 s, and 72°C for 45 s, with final extension at 72°C for 10 min. The genotype results obtained are shown in Table 1 .
Although the genotype distributions of the 825 samples successfully tested by both the LightTyper and RFLP analysis were identical and did not differ from the HardyWeinberg expectations ( 2 ϭ1.97; P ϭ 0.161), we found 2 discrepant samples: 1 typed as GG by the LightTyper and GC by the RFLP method, and 1 typed as GC by the LightTyper and GG by the RFLP method. This represents a concordance rate of 99.75%. These 2 discordant samples were sequenced directly by standard methods (14 ) on an ABI Prism Automated DNA sequencer. Direct sequence analysis confirmed the melting curve analysis results for 1 of the 2 discrepant samples, and in the other sample direct sequencing confirmed the RFLP result. After individually checking the discrepant results, we found that the error in the RFLP method was the result of a partial digestion, which led to a spurious heterozygote result, whereas the error in the LightTyper was the result of background noise for the probe, which generated a "pseudopeak" corresponding to the mutant T m . How-ever, the small amplitude of the peak and the deviation by 2°C from the correct T m suggested its spurious condition in the second revision of results. Regarding the RFLP method, although standard positive digestion controls were included, when hundred of samples are tested, inhibitory factors present in some samples can decrease the enzyme activity, leading to incorrect results. One possible solution is to generate a internal positive control for each sample, as proposed Danneberg et al. (15 ) . Overall, our results indicate that the LightTyper system can successfully detect SNPs with an accuracy similar to that of the RFLP method. The cost in reagents is similar for both methods; therefore, because the LightTyper is quicker, it appears to be a better choice than the standard RFLP method.
Having validated the melting curve analysis obtained with LightTyper for high-throughput genotyping under real biomedical laboratory conditions, using the 56CϾG polymorphism as an example, we also developed an assay to detect the Ϫ1131TϾC polymorphism. We used the LightTyper and SimpleProbe approach with the primers 5Ј-CACATCCCTCTTTATGAAACAAT-3Ј and 5Ј-GTA-GACGGAGTGGGTGTGTCA-3Ј (TIB MOLBIOL) to amplify a 229-bp fragment. PCR was carried out in 384-well plates in a total volume of 10 L containing 40 ng of genomic DNA, 0.2 L of each primer (10 M), 1.6 M SimpleProbe (Flq-AGGAACTGGAGCGAAAGTAAGATTTp; TIB MOLBIOL), 5 U of Fast Start Taq Polymerase (Roche Diagnostics), 1.75 L of 25 mM MgCl 2 , and 200 M each deoxynucleotide triphosphate. The PCR conditions were as follows: initial denaturation at 96°C for 5 min, followed by 40 cycles of 96°C for 45 s, 53.5°C for 45 s, and 72°C for 45 s, with final extension at 72°C for 10 min. The melting curve analysis was performed as indicated above. The T m s were 63.5°C for the wild-type allele (T) and 58°C for the variant allele (C); accordingly, we found 736 individuals who were homozygous TT, 86 who were heterozygous CT, and 3 who were homozygous CC.
Carriers of the less common allele were grouped, and a crude association analysis was carried out (results not shown). The 56CϾG polymorphism was statistically associated (P ϭ 0.04) with higher mean triglyceride concentrations, but the association for the Ϫ1131TϾC SNP did not reach statistical significance (P ϭ 0.21). Nevertheless, a more detailed analysis including control for covariates and an increased sample size is needed in this population. In this regard, it is interesting to note that our allele frequencies for the variant alleles (particularly for the Ϫ1131TϾC polymorphism) were slightly lower than those reported in other populations (7, 8 ) .
Finally, to take a full advantage of this new technique, we also tested several primer concentrations in asymmetric PCR assays and found that forward/reverse primer ratios of 0.26 for 56CϾG and 0.20 for Ϫ1131TϾC improved PCR efficiency, decreasing the failure rate near to 0%.
We gratefully acknowledge F. Gimenez-Fernández for laboratory assistance. F.F. is the recipient of a fellowship from the University of Valencia (V Segles). This work was Venous thrombotic events are quite common; they affect ϳ1 in every 1000 persons per year and have a lifetime clinical prevalence of ϳ5%. The pathogenesis of venous thrombotic events is complex, involving the interaction of acquired risk factors with some genetic predisposition.
A wide array of methods and technologies have been used for screening of prothrombotic mutations (1-4 ) . However, it is known that when mutation detection methods other than direct sequencing are used to identify a particular sequence change, there is always some risk that other sequence alterations occurring at the recognition site could lead to allele misclassification.
This issue has been discussed, for example, for the silent A1692C polymorphism in the factor V gene, which is erroneously identified as factor V Leiden by restriction enzyme digest detection (5 ) . Other genotyping methods could also be affected by adjacent sequence alterations, including allele-specific amplification (6 ), single-strand conformational polymorphism analysis (7 ), oligonucleotide ligation (8 ) , heteroduplex analysis (9 ), and methods based on melting curve analysis, in which unexpected results should be clarified definitively by sequencing (10 ) .
Although DNA sequencing is still considered the "gold standard" for characterizing specific nucleotide alterations and improved technology has made automated DNA sequencing available to the clinical molecular diagnostics laboratory, DNA sequencing remains too expensive and time-consuming for most applications.
Recent studies demonstrating the robustness and speed of pyrosequencing technology, as well as its possible use for multiplex genotyping (11 ) , have led to its use in an increasing range of genetic research areas (12) (13) (14) (15) .
The aim of our work was to establish a multiplex protocol for direct pyrosequencing analysis of a panel of coagulation factors mutations: the 3 single-nucleotide polymorphisms (SNPs) most commonly associated with thrombophilia-G1691A in factor V Leiden, G20210A in factor II, and C677T in methylenetetrahydrofolate reductase (MTHFR)-for a first-tier screening, and 3 additional polymorphisms-A1298C in MTHFR, Val34Leu in factor XIII, and 4G/5G in plasminogen activator inhibitor-1 (PAI-1)-which are believed not to have an independent effect on venous thrombosis but could be investigated in a second-tier screening because they may act synergistically with the previously mentioned factor mutations (16, 17 ) or, in the case of factor XIII Val34Leu, exert a protective effect (18 ) .
We used pyrosequencing to genotype 100 individuals, previously analyzed by LightCycler (Roche) or by direct sequencing, for all 6 polymorphisms. Pure genomic DNA from EDTA-anticoagulated blood was isolated either by use of the semiautomated Magna Pure instrument with the Magna Pure LC DNA Isolation Kit (Roche) or manually, with the High Pure PCR Template Preparation Kit (Roche). These extraction procedures gave the same yield and PCR performance.
The 6 genomic segments containing the SNPs of interest were amplified in triplex PCR reactions with 3 pairs of primers (Eurogentec; see Table 1 ).
PCR conditions were optimized in preliminary experiments in which amplified products were analyzed by electrophoresis on agarose gel (4%) to optimize template 1282 Technical Briefs concentration, magnesium concentration, and number of cycles to enhance PCR yield and specificity, which improve the success of the sequencing reaction.
Optimal PCR conditions for triplex amplification of factor V Leiden, factor II G20210A, and MTHFR C677T were as follows: 10 ng of pure genomic DNA, 10 pmol of each primer, 200 M each deoxynucleotide triphosphate (dNTP), 3 mM MgCl 2 and 0.5 U of HotGoldStar Taq polymerase (Eurogentec) in 20 L (final volume) of the buffer supplied (Eurogentec). Thermal cycling started with 10 min at 95°C followed by 35 cycles of 95°C for 30 s, 59°C for 30 s, and 72°C for 60 s, with a final step at 72°C for 5 min.
Triplex amplification of factor XIII Val34Leu, PAI-1 4G/5G, and MTHFR A1298C was performed with the following conditions: 10 ng of pure genomic DNA, 4.5 pmol of factor XIII primers, 25 pmol of MTHFR primers, 9 pmol of PAI-1 primers, 200 M each dNTP, 1.5 mM MgCl 2 , and 0.5 U of HotGoldStar Taq polymerase in 30 L (final volume) of the buffer supplied (Eurogentec). Thermal cycling started with 10 min at 95°C, followed by 40 cycles of 95°C for 30 s, 58°C for 45 s, and 72°C for 60 s, with a final step at 72°C for 5 min.
At the end of PCR, 20 -30 L of each biotinylated PCR products was immobilized on 3 L of streptavidin-coated Sepharose beads (Amersham Biosciences) to obtain singlestranded DNA suitable for sequencing. The immobilization, denaturation, washing, and primer annealing steps were performed with a vacuum preparation workstation according to the manufacturer's instructions (Biotage AB).
The single-stranded biotinylated PCR products were subjected to a multiplex minisequencing reaction on a PSQ96MA instrument (Biotage AB) to interrogate 3 polymorphic loci simultaneously. The multibase reading capability of pyrosequencing facilitates optimal positioning of the sequencing primers (Table 1) . Sequencing was performed as described previously (19 ) . The dispensation order to analyze the 3 sequences at the same time was selected by use of the SNP Entry module of the SNP Analysis Software (Biotage AB).
Parallel processing of 96 samples markedly reduced the handling time and pipetting steps needed. The maximum throughput was limited only by the number of PCR reactions because the multisequencing reaction lasted only 23 min for each 96-well microtiter plate. In addition, the results from the 96 completed sequencing reactions were analyzed by the pyrosequencing software in 2 min and were displayed as shown in Fig. 1 and in Fig. 1 of the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/ vol51/issue7/. Sequences are determined by computer-automated comparison of predicted patterns with raw data.
Generally, samples did not require time-consuming manual interpretation. Failure to make a genotype call at the first attempt was infrequent (ϳ5%) and was mostly attributable to insufficient signal-to-noise ratios caused by poor PCR amplification. The accuracy, robustness, and reproducibility of the assay were very high: 100% of the results obtained with pyrosequencing (Table 1 of the online Data Supplement) were confirmed by LightCycler or sequencing analysis.
In conclusion, this method is rapid and cost-effective when compared with traditional sequencing; it is also suitable for the present challenge of high-throughput SNP genotyping: including all reagents and PCR, the cost per sample was 3 €. This study shows, as has been shown previously, how a technology originally introduced into the field of basic biomedical research can be successfully adapted to the clinical laboratory. (Top), the x axis shows the dispensation order of dNTPs during pyrosequencing; the y axis shows peak heights representing the intensity of the light signal produced, which is proportional to the number of dNTPs incorporated into the DNA templates. (Bottom), genotypes are assigned by computer-automated comparison of peaks with predicted histograms. The individual shown in this figure was heterozygous for MTHFR C677T (u) and homozygous wild type for factor V G1691A ( ) and factor II G20210A (f).
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Technical Briefs typically missense within exons 4 -9, impairing the capacity of p53 to transactivate genes involved in cell cycle arrest, apoptosis, and DNA repair (1 ) . Functionally, mutations may differ according to their nature and position, as well as to the presence of a common polymorphism at codon 72 (arginine or a proline) in the mutant allele (2 ) . Knowing TP53 mutation status has potential applications for cancer prognosis (3, 4 ) and early diagnosis (5 ), identification of mutagen "fingerprints" (1, 6 ) , and prediction of therapeutic outcomes (7, 8 ) . To achieve this purpose, sensitive, fast, and cost-effective methods are needed to assess the whole coding sequence plus exon/intron boundaries. Current approaches are based on mutation prescreening with single strand conformational polymorphism analysis, temporal temperature gradient electrophoresis, or denaturing HPLC (DHPLC) combined with direct sequencing of relevant PCR fragments [reviewed in Ref. (9 )]. These methods are labor-intensive, difficult to standardize, and in some cases, of limited sensitivity. In recent years, 2 microarray methods for resequencing TP53 have been described: the Affymetrix p53 GeneChip array, described elsewhere (10, 11 ) , and the Arrayed Primer Extension (APEX), based on incorporation of 4 dye terminators into oligonucleotide primers that each identify a base in the target sequence (12 ) . In 2002, we described an APEX array for resequencing TP53 exons 2-9, which contain 95% of known mutations in TP53 (13 ) . Here we compare the sensitivity and detection limits of APEX with a standard method, DHPLC/direct sequencing, and discuss the potential of APEX for application to cancer diagnostic or prognostic purposes.
Specimens in the comparison set included 6 cell lines with mutations in different TP53 exons (see Table 1 vol51/issue7/) and 60 tumor samples with TP53 mutations identified by DHPLC (exons 4 -9) and direct sequencing (29 from paraffin-embedded lung cancers and 31 frozen specimens of oral cancers). The persons performing the APEX screening (exons 2-9) were blinded to mutation status. Mutations in these specimens were representative of the diversity of TP53 mutations in human cancers. Four specimens positive by DHPLC but with no mutation found by sequencing were also tested. DNA extractions, PCR, DHPLC, and sequencing were performed according to described protocols (see Tables 2 and  3 of the online Data Supplement) (14 ) . APEX probes were 25mer oligonucleotides with 12-carbon amino linkers at their 5Ј end covering the sense and antisense wild-type TP53 sequence (Genset) and were spotted on 24 ϫ 60 mm SAL-type aminosilane/ phenylene diisothiocyanate-coated microarray slides (15 ) . PCR products were concentrated and purified by use of the Jet quick PCR purification Spin Kit (Genomed). Hybridization and primer extension reactions were performed as published previously (13 ) . Data were analyzed with Genorama TM 4.2 genotyping software, using clustered signal patterns from 20 wild-type TP53 DNA sequences as statistical reference. For each position, the software calculates the distance (difference) between the sample signal and the signal pattern of the wild-type reference cluster database [algorithm described by Tonisson et al. (13 ) ]. The distance value is used as a measure for calling the given base. Zero distance indicates a perfect match between the given base and the wild-type reference. The default cutoff distance value of the software with cluster analysis is 30 but can be adapted by the user.
A representative analysis of a TP53 exon 7 mutation at codon 236 (TACϾTGC) is shown in Fig. 1 . To evaluate APEX detection limits, defined amounts of PCR products of DNA from 6 cell lines homo-or hemizygous for known mutations were mixed with wild-type PCR products and analyzed in parallel by DHPLC and APEX. An example of DHPLC and APEX detection limits is given in Fig. 1 of the online Data Supplement. With DHPLC, detection limits showed variations depending on mutation type and mutation sequence context (Table 1) . With APEX, all mutations were detected with detection limits of 3.125%-6.25%, consistent values reported previously for codons 273 (CGTϾCAT) and 248 (CGGϾTGG) (13 ) . In comparison, direct sequencing does not detect most mutations in samples containing less than 25%-30% mutated DNA (16, 17 ) . Of 66 TP53 mutations identified by DHPLC/ sequencing in 60 tumors, APEX identified 62 but failed to detect 4 mutations (sensitivity, 94%; see Table 4 of the online Data Supplement). All mutations occurred between exons 4 and 9. Among substitutions, 49 of 52 (94.2%) were correctly identified by APEX. Two of the mutations that escaped APEX detection (codon 91, TGGϾTGA and codon 174 AGGϾTGG) corresponded to positions generating background signals in one DNA strand. The third one (codon 173 GTGϾATG) was identified on the antisense strand only because of inefficient hybridization at this position. APEX specificity and sensitivity may be further improved by experimentally establishing cutoff values for mutants at each position of the APEX array or by modifying probe design to minimize the formation of secondary structures interfering with DNA hybridization.
The 14 other mutations detected by DHPLC/sequencing were deletions or insertions. APEX correctly identified 1 insertion (ϩ 1 bp; codons 62-63) and detected the base change at one extremity in 12 other cases (85.7%), including 4 insertions ranging from 1 to 8 bp, 7 deletions ranging from 1 to 4 bp, and 1 rearrangement at codon 184 that was not clearly identified as an insertion or deletion by sequencing. However, in these 12 cases, APEX did not allow complete identification of the change in DNA sequence. Overall, APEX had a sensitivity of 93% in detecting insertion/deletions, but only 7% in fully identifying their positions and sizes. These limitations are intrinsic to APEX design, which is based on hybridization of wildtype sequences to complementary, immobilized oligonucleotides (18 ) . In theory, the presence of a deletion should lead to incorporation of an unexpected nucleotide at the 5Ј border of the deletion and corresponding to the first nucleotide flanking the 3Ј border of the deletion. Presence of an insertion should generate an unexpected signal corresponding to the first inserted base at the 5Ј border of the insertion. However, these events will be detectable only if the signals they generate differ from expected wild-type signals at these positions. Assuming equal distribution of insertions and substitutions at all base positions, there is a 1 in 4 chance for either strand that the border may be undetectable and a 1 in 16 chance that the sequence alteration escapes detection. However, in practice, the odds for nondetection are higher because insertions and deletions often occur within singlebase repeats, making it likely that the modified signal may be identical to the expected one. The nonrandom distribution of insertions/deletions in TP53 may explain the relatively poor performance of APEX in mapping both borders of insertions/deletions. Despite these limitations, APEX compares well with the Affymetrix GeneChip p53 in detecting deletions and insertions (11, 17, 19, 20 ) . Indeed, the latter does not allow detection of sequence alterations unless representative mutant oligonucleotides have been spotted on the array (10, 11 ) .
Of the 4 specimens positive by DHPLC but negative by sequencing, APEX detected base changes in 3, including 1 specimen with 2 mutations (a 1-bp substitution in intron 5 and a silent mutation at codon 147; see Table 4 of the online Data Supplement). Finally, in 5 specimens, APEX generated several signals (2 or 3 per specimen), only one of which was confirmed by sequencing (see Table 4 of the online Data Supplement). The unconfirmed signals by DHPLC/sequencing were detected only on 1 DNA strand by APEX, suggestive of an insertion or deletion as discussed above. Thus, none of these discordant changes were single-base substitutions. We interpreted the discordant signals as "false-positive" APEX signals, which gave 1286 Technical Briefs an overall positive predictive value for APEX of 92.5% (62 of 67).
We found that both fresh-frozen and formalin-fixed, paraffin-embedded tissues are suitable for mutation detection by APEX. The positive predictive values for APEX were 92% (33 of 36) and 93.5% (29 of 31) for frozen and paraffin-embedded tissues, respectively. Thus, the use of paraffin archives did not lead to a higher number of ambiguous or artifactual signals.
The second base of codon 72 harbors a common polymorphism in TP53 that affects a BstUI digestion site. The concordance between APEX and either restriction digestion or DHPLC/sequencing data was perfect for all 64 specimens analyzed (see Fig. 2 of the online Data Supplement). This polymorphism may play a role in cancer susceptibility (21, 22 ) and response to therapy (2 ) . Recently, Bonafe et al. (23 ) reported that preferential loss of the codon 72P allele in breast tumors of heterozygous patients was associated with a significant decrease in disease-free and overall survival. Additional studies have shown an improved response to chemo-radiotherapy and a longer overall survival in patients whose squamous cell carcinomas tumor retained a wild-type 72R allele rather than a wild-type 72P allele (24 ) . Thus, genotyping of TP53 at codon 72, combined with mutation detection, may be relevant for the therapeutic management of cancer. APEX also genotyped 2 other, less frequent polymorphisms at codons 213 (CGA/CGG) and 36 (CCG/CCA) for which concordance between DHPLC and APEX was also perfect.
In conclusion, APEX offers a flexible, sensitive, and low-cost resequencing alternative for large-scale studies involving retrospective analysis of pathology collections as well as for application to studies for which fresh-frozen materials are available. Deficiency of glucose-6-phosphate dehydrogenase (G6PD) is the most common inherited metabolic enzyme disorder in the world, with a very high incidence throughout the tropics and subtropics as a result of malarial selection (1) (2) (3) . More than 140 mutations or combinations of mutations of the X-linked gene for G6PD have been characterized at the DNA level from different ethnic populations worldwide (4, 5 ) . In areas of Southeast Asia, including southern China, at least 25 deficiency-causing point mutations have been identified in the human G6PD gene. Ten mutations (95A3 G, 392G3 T, 487G3 A, 493A3 G, 592C3 T, 871G3 A, 1024C3 T, 1360C3 T, 1376G3 T, and 1388G3 A) account for Ͼ80% of all known mutations in Southeast Asian countries (4 -8 ) .
Rapid
The current molecular approaches to identifying G6PD-deficiency-causing mutations rely on various methods for allele differentiation (7) (8) (9) (10) . Each of these approaches has advantages and limitations, but the technical aspects and/or cost have limited their routine use in most laboratories. Rapid and accurate genotyping of G6PD-deficiency-causing mutations is necessary to meet the requirements for genetic counseling, genetic epidemiology, and clinical molecular diagnosis of this disorder.
We have developed a multiplex primer extension/fully denaturing HPLC (PE/DHPLC) assay capable of simultaneously detecting the above 10 G6PD mutations and 1 common polymorphism (1311C3 T) (11 ) . Eleven genomic DNA samples with different known genotypes, including the above 11 G6PD mutations and the silent polymorphism as previously determined by direct sequencing, were used to validate this application. A total of 209 blood samples with various G6PD-deficiency-causing mutations, the silent polymorphism, or the wild-type G6PD gene sequence identified by direct sequencing were obtained to test the specificity of this assay by blind analysis. The genotypes of these DNA samples are shown in Table  1 of the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem. org/content/vol51/issue7/.
Multiplex PCRs were designed to produce sequences of interest in the G6PD gene, to be used for detection by the PE reaction, and generated 370-, 967-, and 1041-bp fragments (GenBank accession number X55448), respectively. Eleven oligonucleotides for specific genotyping of the 11 different mutations were designed according to the previously published sequence [(4, 12 ) ; Table 1 and Fig. 1 in the online Data Supplement] and were used in 2 separate groups for multiplex PE. The basic principle for identification of point mutations by this method is PE-based specific detection (13 ) . Because the separation of oligonucleotides by DHPLC is both size and sequence dependent under fully denaturing conditions, modification of some of the oligonucleotides was necessary to provide an easily interpretable genotype pattern (14 ) . The multiplex PCR was performed in a total volume of 25 L containing 12.5 L of 2ϫ PCR Master Mix [including deoxynucleotide triphosphates (dNTPs), buffer, MgCl 2 , and Taq DNA polymerase (Promega)], 0.2 g of genomic DNA, 0.2 M each of the primers for fragment 1 (5Ј-GACCCCAGAGGAACTCTCAA-3Ј and 5Ј-CAGGTA-GAGCCGGGATGAT-3Ј), 0.6 M each of the primers for fragment 2 (5Ј-ACGATGATGCAGCCTCCTAC-3Ј and 5Ј-GTTCTGCACCATCTCCTTGC-3Ј), and 0.8 M each of the primers for fragment 3 (5Ј-CCTGAGGGCTGCA-CATCT-3Ј and 5Ј-CCTTTCCTCACCTGCCATAA-3Ј). The final volume was adjusted to 25 L with water. For amplification, an initial 2-min denaturation at 95°C was followed by 14 "touchdown" cycles of 94°C for 30 s, 62°C for 30 s (with a temperature decrease of 0.5°C/cycle for 14 cycles to 55°C), and 72°C for 1 min 30 s; 20 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min 30 s; and a final extension at 72°C for 5 min. PCR was carried out in an Applied Biosystems 9700 thermal cycler (PerkinElmer). Excess primers and dNTPs were removed from the multiplex PCR reaction by use of exonuclease I (US Biochemicals) and shrimp alkaline phosphatase (Roche Diagnostics) digestion. Two units of each enzyme were added directly to 20 L of PCR reaction mixture, mixed, and incubated at 37°C for 25 min followed by 94°C for 5 min to inactivate the enzymes.
The multiplex PE reactions were carried out in a final volume of 20 L containing the following: 50 M each dideoxynucleotide triphosphate (ddNTP) except for the replacement of ddGTP by dGTP (Amersham Biosciences) in the group 1 reaction, 0.5 M each primer, 0.5 U of Thermo Sequenase (Amersham), 4 L of purified PCR product, and 2 L of 10ϫ reaction buffer provided by the manufacturer. The PE reactions were performed on an Applied Biosystems 9700 thermal cycler under the following conditions: an initial 1-min denaturation at 96°C was followed by 50 cycles of 96°C for 5 s and 65°C for 15 s. This step for groups 1 and 2 used the same PE thermocycling profile.
DHPLC analysis was conducted on the automated WAVE DNA Fragment Analysis System (Transgenomic). Briefly, 5 L of each PE product was injected into the mobile phase (buffer A, 0.1 mol/L triethyammonium acetate; buffer B, 250 mL/L acetonitrile in 0.1 mol/L triethylammonium acetate) at 0.9 mL/min flow rate. The W, wild type; M, mutant. The negative control illustrates the elution times of the oligonucleotides with no PE products present. The positive control is a mixture of all 6 or 5 mutant G6PD allele samples as a template for PCR followed by PE. Genotypes and sample numbers are labeled to the left of the chromatogram. Group 1 for detection of 6 mutations and group 2 for detection of 5 mutations are illustrated separately. There are samples from 7 males (hemizygotes) and 9 females (heterozygotes or homozygotes) in these 2 DHPLC profiles, including 5 samples for compound heterozygotes (samples 77, 110, 143, 195 , and m55), 1 sample from a homozygote (sample 43), and 1 sample from a compound hemizygote (sample 160), of which 4 showed positive specific mutant peaks in both groups for their detection (samples 143, 160, 195, and m55) .
Clinical Chemistry 51, No. 7, 2005 primer extension products were eluted from the solid phase (DNASep cartridge; Transgenomic) by a linear gradient (18%-39% buffer B) in an 11-min sample run under fully denaturing conditions (70°C). The eluted products were detected by their ultraviolet absorbance at 260 nm.
We established 2 groups of multiplex PE reactions for detection of 10 G6PD-deficiency-causing mutations and 1 silent polymorphism; these reactions can simultaneously detect 6 (group 1) or 5 mutations (group 2). Representative DHPLC profiles for genotyping these 11 G6PD mutations are shown in Fig. 1 . In this technique, there are 3 possible DHPLC profiles for each potential mutation, which have been described previously (14 ) , except that a primer peak plus a mutant peak (M in Fig. 1 ) indicates a hemizygous mutation in men, because the G6PD gene is X-linked, or a homozygous mutation in women. In addition, we noted that the heterozygous mutation was identified only in female samples. In a blind analysis, 208 of the 209 samples tested (99.5%) were found to be in concordance with the DNA sequencing data; the exception involved 1 sample that gave a false-positive (genotype of 1376/1388) result in the PE assay but no 1376G3 T mutation in sequence analysis.
The combination of extension primers for each group was chosen to obtain well-distributed and easily interpretable DHPLC profiles. We assembled primers A, B, E, H, J, and K in group 1 with substrates of dGTP and 3 ddNTPs and primers C, D, F, G, and I in group 2 with the substrates being the 4 ddNTPs (Table 1) so that highquality profiles for genotyping each of the mutations were produced. In our experience, the highest numbers of multiplex oligonucleotide products that can be detected in 1 DHPLC test is 8 because of limitations of retention time and other conditions. We propose that "building blocks" of 5 mutations be a general rule for designing multiplex PE assays using fully denaturing DHPLC analysis on the Wave system. To establish the identities of grouped PE products without overlapping of peaks, the design of primers and their combination based on substrates (ddNTPs and dNTPs) should be the main considerations for PE/DHPLC optimization. In addition to this, one needs to pay close attention to column equilibration in the PE/DHPLC application. Nonequilibration of a column may cause a shift in retention time, low peak intensity, broader peak patterns, or even split peaks. To avoid this, use only the "Normal Clean" setting on the WAVE DNA Fragment Analysis System. Therefore, buffer B is used for column cleaning. A couple of blank injections between sample injections are also recommended to ensure column equilibration.
We noticed that some samples from hemizygous and homozygous individuals had similar DHPLC profiles that were missing the wild-type peak. It therefore is necessary Great interindividual variability in drug response leads to variation in drug safety and efficacy. Although this can be the result of environmental and physiologic factors as well as drug-drug interactions, in many cases the response is inherited, arising from a polymorphism in genes encoding drug transporters, drug receptors, and especially, drug-metabolizing enzymes. The polymorphic cytochrome P450 2D6 (CYP2D6; OMIM 124030) is one of the most widely studied drug-metabolizing enzymes, being responsible for the metabolism of many commonly used drugs belonging to classes such as antidepressants, neuroleptics, beta-blockers, and antiarrhythmics (1 ). The CYP2D6 gene spans a 4.2-kb region located on chromosome 22q13.1 and is part of the CYP2D cluster together with CYP2D8P and CYP2D7 pseudogenes (2 ) . At present, more than 50 different major polymorphic CYP2D6 alleles are known (3 ). These include variants produced by major rearrangements (whole-gene deletion or duplication), point mutations, and single or multiple base deletions or insertions. The phenotypic consequences of this variation are considerable: the CYP2D6 enzyme activity ranges from complete deficiency, possibly giving rise to profound toxicity of medication in the case of poor-metabolizing individuals, to ultrarapid metabolism, which can lead to therapeutic failure at recommended drug dosages. Individuals with a normal or slightly below normal rate of metabolism related to the CYP2D6 enzyme are usually defined as extensive or intermediate metabolizers, respectively.
CYP2D6 genotyping to predict metabolic status is considered a valid alternative to traditional phenotyping methods (4 ) . Assessing the CYP2D6 genotype also offers several distinct advantages over the experimental determination of a CYP2D6 phenotype (5 ) . The characteristics of the gene do not change during the lifetime, and genetic Clinical Chemistry 51, No. 7, 2005 status is uninfluenced by environmental or physiologic factors. Genotyping requires only 1 sample and can be done before a drug is given to a patient. It therefore may facilitate improved drug efficacy and diminished risk for adverse drug reactions (6 ) . At present, there are specific guidelines available on how genetic information could be taken into account in clinical dose adjustments for specific antidepressants and antipsychotics (7 ) . Furthermore, in forensic medicine, CYP2D6 genotyping may provide important information on whether a polymorphism may have contributed to a drug fatality.
Because CYP2D6 genotyping has a wide range of applications in both routine and research investigations, methods for rapid and cost-effective genotyping are necessary. Different genotyping methods for the CYP2D6 gene have been developed, including multiplex allelespecific PCR (8 ), PCR with restriction fragment length polymorphism (PCR-RFLP) analysis (9 ), real-time PCR (10 ), pyrosequencing (11 ) , and oligonucleotide microarray technology (12 ) . Despite allele-specific PCR and RFLP analysis being laborious and low throughput, these methods are still widely used (13, 14 ) because the newer, high-throughput methods often require special laboratory facilities (15 ) . Our aim was to develop a rapid and technically feasible genotyping method that is suitable for moderate-throughput laboratories and includes all clinically important CYP2D6 mutations that are known to alter the enzyme activity.
In this study, we describe a CYP2D6 genotyping protocol based on a combination of PCR and multiplex extension of unlabeled oligonucleotide primers with fluorescently labeled dideoxynucleotide triphosphates (SNaPshot TM ; Applied Biosystems). The method has been designed to screen whole-gene deletion and duplication and 11 of the most relevant polymorphic positions of the gene (Table 1) as well as the allelic composition of the gene duplication. It allows the identification of CYP2D6 alleles highly represented in different human populations (i.e., *2, *4, *10, *17, *29, *39, and *41) or alleles, even if rare, known to be responsible for low or null metabolic activity (i.e., *3, *6, and *9) (16 ) . Alleles *10 and *17, in particular, have been included to extend the usability of the method because these are considered to be the major decreasedfunction variants in Asian and African populations, respectively. Alleles not carrying detected mutations were classified as *1.
The entire CYP2D6 gene (5.1 kb) was amplified in long-PCR reaction using primers CYP2D6-F (5Ј-CCA-GAAGGCTTTGCAGGCTTCA-3Ј) (17 ) and CYP2D6-R (5Ј-ACTGAGCCCTGGGAGGTAGGTA-3Ј) (17 ) to separate the gene from the flanking highly homologous CYP2D8P and CYP2D7 pseudogenes. The 50-L reaction mixture contained 1.5 U of GeneAmp ® rTth DNA Polymerase XL (Applied Biosystems), 1ϫ XL Buffer II, 1.25 mM Mg(OAc) 2 , 0.2 mM each deoxynucleotide triphosphate, 0.4 M each primer, and 20 -100 ng of genomic DNA. The PCR was conducted as follows: denaturation at 94°C for 1 min; 10 cycles of 94°C for 30 s and 68°C for 10 min; 25 cycles of 94°C for 30 s and 68°C for 10 min and 15 s, plus 15 s per cycle; and a final extension at 72°C for 30 min. Two additional long-PCR reactions were used to analyze the major rearrangements, i.e., duplication or deletion, of the entire CYP2D6 gene. We amplified a duplication-specific 3.2-kb fragment, using primers CYP-207-F (5Ј-CCCTCAGCCTCGTCACCTCAC-3Ј) (18 ) and CYP-32-R (5Ј-CACGTGCAGGGCACCTAGAT-3Ј) (18 ) . To rule out false-negative results, we added primer CYP-13-F (5Ј-ACCGGGCACCTGTACTCCTCA-3Ј) (19 ) to the reaction mixture, which yielded an internal control fragment of 3.8 kb. To detect the gene deletion, we again used a set of 3 primers; we amplified a deletion-specific 3.5-kb fragment and a 3.0-kb control fragment, using primers CYP-13-F, CYP-24-R (5Ј-GCATGAGCTAAGGCACCCA-GAC-3Ј) (19 ) , and CYP-207-F. The 50-L reaction contained 1.0 U of DyNAzyme TM EXT DNA Polymerase (Finnzymes), 1ϫ magnesium-free EXT buffer, 1.0 mM MgCl 2 , and 0.2 mM each deoxynucleotide triphosphate. The primer concentrations were as follows: for the duplication-specific reaction, we used 0.6 M CYP-207-F, 0.4 M CYP-32-R, and 0.2 M CYP-13-F; and for the deletion- a The first number in the primer name describes the length of the primer, and the second refers to the SNP position. b Intronic position 2988 has been considered as defining allele *41 because the predictivity of this mutation for impaired enzyme function has been demonstrated recently (27 ) .
1292
Technical Briefs specific reaction, 0.6 M CYP-13-F, 0.4 M CYP-24-R, and 0.2 M CYP-207-F. The temperature cycling profile was the same as described above. The long-PCR products were analyzed on 1% agarose gels (Fig. 1A) , and the 5.1-kb fragments were purified by use of 1 L of ExoSAP-IT ® (USB Corporation) per 5 L of PCR product, with incubation at 37°C for 15 min and at 80°C for 15 min to successively deactivate the enzymes.
The purified 5.1-kb product was used as a template to detect 11 polymorphic positions of the CYP2D6 gene (Fig.  1B and Table 1 ). In the following single-base extension reaction, the detection primers annealed adjacent to the single-nucleotide polymorphism (SNP) position. A difference of 5 nucleotides between primer lengths was chosen to avoid overlapping between the fluorescent signals of the final products in the capillary electrophoresis. To achieve the final length, 5Ј poly(dT) tails were added to the primers. The sequences of the detection primers and their final concentrations in the reaction are listed in Table  1 . The SNaPshot reaction contained 2.0 L of purified PCR product, 2.0 L of pooled detection primers, and 2.5 L of SNaPshot ready reaction mixture in a final volume of 10 L. The temperature cycling profile was 25 cycles of 96°C for 10 s, 55°C for 10 s, and 60°C for 30 s. After the reaction, 5Ј-phosphoryl groups of unincorporated dideoxynucleotide triphosphates were removed by addition of 1.0 U of calf intestinal phosphatase (Finnzymes) and incubation of the samples at 37°C for 1 h and at 75°C for 15 min to successively deactivate the enzyme. Capillary electrophoresis of samples was performed on the ABI PRISM ® 3100 genetic analyzer, and the results were analyzed with GeneMapper ID, Ver. 3.1 (Applied Biosystems; Fig. 1C ). Electropherograms presenting different CYP2D6 alleles are shown in Fig. 1 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/vol51/ issue7/.
We have used the method to genotype the HGDP-CEPH Human Genome Diversity Cell Line Panel, which includes 1064 individuals [Ref. (20 ) ; our unpublished data]; 247 samples extracted from fresh blood (21 ) , and Ͼ200 postmortem cases. Altogether, these samples represent a worldwide distribution of populations; thus each detected mutation was found in at least 8 individuals. For method validation, we selected a subset of 50 individuals from the above-mentioned samples, representing all different detected alleles, and genotyped them by PCR-RFLP analysis (9, 22 ) . The minimum allelic frequency in the subset was 3% (at least 3 chromosomes bearing the mutation). Polymorphic positions 2988GϾA and 3183GϾA, which were not included in our PCR-RFLP protocol, were verified by sequencing 5 carriers and 2 noncarriers according to the SNaPshot profile. In addition, we performed a SNaPshot genotyping to reanalyze 33 postmortem cases typed previously by PCR-RFLP analysis (22 ) . Concordance was 100% between the new method and the conventional methods.
A new and interesting feature of our genotyping protocol is the possibility of determining the phase of gene duplication. We observed that the SNaPshot reaction described above presents as a byproduct a quantitative aspect, and we believe that it provides adequate information to determine which of the 2 alleles is actually duplicated ( Fig. 1C ; also see Fig. 2 in the online Data Supplement). To confirm the previous result, we selected 11 samples from the CEPH dataset that were found duplication-positive (2 *1xN/*2, 2 *1/*2xN, 1 *1xN/*4, 2 *1/*4xN, 2 *2xN/*4, and 2 *2/*4xN). We amplified a 9.3-kb fragment (Fig. 1A) , using primers Lx2F (5Ј-GCCACCATGGT-GTCTTTGCTTTC-3Ј) (23 ) and Lx2R (5Ј-ACCGGATTC-CAGCTGGGAAATG-3Ј) (23 ) . The reaction conditions and the temperature cycling profile were the same as described for the 5.1-kb fragment. The amplified region starts from exon 9 and ends at intron 2 of the 2 subsequent CYP2D6 genes. Three polymorphic positions, namely 4180 of the first gene and 100 and 1023 of the second gene, were examined by nested PCR-RFLP analysis. The duplicated genotype identifications obtained through the original 11-plex SNaPshot reaction were confirmed in all cases.
From our experience, the SNaPshot method is very robust, accurate, and easy to perform. Advantages of the SNaPshot technique include the detection of high numbers of mutations in a single reaction and the possibility to increase the number of detected SNPs without substantially increasing the costs of analysis. With our method the cost per genotype is ϳ5 € (from long PCR to the capillary electrophoresis), which is less than one-half the cost of the corresponding PCR-RFLP analysis. Samples can be processed in 96-well plates, and after the overnight PCR, the final genotypes can be obtained in 5 h.
In summary, we designed a cost-effective and technically feasible CYP2D6 genotyping technique through a 2-step assay that provides a straightforward interpretation of results. It allows detection of 11 of the most relevant polymorphic positions, the assessment of wholegene deletion and duplication, and unlike most available typing methods, the allele composition of the gene duplication. The latter feature may be useful in the prediction of phenotype; a clear example is the difference between the genotype CYP2D6*1/*4xN, which produces a single full-function allele, and genotype CYP2D6*1xN/*4, which will produce at least twice the amount of enzyme.
Methods using the same principle have recently been published (24, 25 ) , but to our knowledge this is the most exhaustive CYP2D6 SNaPshot assay in terms of number and type of polymorphic positions and validation. Covering the most frequent and clinically relevant CYP2D6 mutations, this method can be used in routine and research investigations worldwide. This feature is particularly important considering the mixed genetic background of modern societies (26 ) . In addition, the results obtained by the proposed combination of PCR and SNaPshot were confirmed, with no exceptions, by conventional methods. This was true for both the definition of the 11 SNP haplotypes and the phase of gene duplication. The method is suitable for moderate-throughput laboratories and is easily extended to alternative or additional SNPs in the targeted CYP2D6 gene region.
